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ABSTRACT 
 
Purpose:  To investigate the expression and exogenous effect of Leptin hormone in diseased parathyroid 
glands at a basic science and clinical level. 
 
Introduction:  Hyperparathyroidism (HPTH) is a common endocrine problem affecting 1 in 500 
individuals who are typically female and over the age of 60. Combined effects of low calcium and 
vitamin D stimulating parathyroid activity and excess PTH secretion are well established, especially in 
secondary HPTH. Unclear is the mechanism behind the development of hyper secreting parathyroid 
adenomas, responsible for nearly 90% of primary HPTH. Discovered in 1994 as a class 1 cytokine 
receptor, leptin has mounted considerable interest as a mitogenic factor involved in the stimulation and 
growth of tumors. Also, leptin has been implicated in multiple calcium related metabolic processes, which 
have led to numerous evaluations of the connections between vitamin-D, PTH, and obesity. Ultimately, 
these scientific findings, the prevalence of higher leptin levels in women with HPTH, and our hypothesis 
that leptin found with increased body weight contributes to the pathogenesis of HPTH, has led to our 
study on endogenous leptin production and its exogenous effect in diseased parathyroid glands. 
Furthermore, with routine serum calcium screening now, many patients are treated with minimally 
invasive parathyroidectomy (MIP) before hypercalcemic sequelae develop; we also wished to clarify the 
clinical relationship between PTH, leptin, and BMI in a cohort of patients with HPTH undergoing 
surgery. 
 
Methods:  We enrolled 96 patients with HPTH undergoing MIPs in a prospective study to collect tissue 
and colocalize leptin hormone and PTH by in-situ hybridization (ISH), immunohistochemistry (IHC), 
immunofluorescence (IF), and electronmicroscopy (EM). Cell culture and whole organ explant 
experiments in which surgically removed human parathyroid tissue were exposed to recombinant human 
leptin to functionally characterize the effect of leptin on PTH secretion. Parathyroid adenomas and 
hyperplasia were xenografted into nude rats and evaluated for the production of human leptin. Blood was 
also collected to assess subsequent perioperative changes to serum leptin levels. Patients WITHOUT 
HPTH undergoing hemithryoidectomies under identical surgical conditions were enrolled as control 
subjects. Wilcoxon signed-rank test, non-parametric version of paired t-test, and pearson correlations 
were used to compare leptin level changes and with different clinical variables using SAS 9.2. 
 
Results:  Leptin, leptin receptor, and PTH mRNA transcripts and protein were detected in an overlapping 
fashion in secretory (chief) cells in parathyroid hyperplasia and adenoma samples by ISH, IHC, IF, and 
EM studies. Immunofluorescence studies under spinning disc confocal microscopy and electron 
microscopy imaging confirm co-localization of endogenous leptin and PTH as well as active exogenous 
leptin uptake in cultured parathyroid cells. Tissue explant experiments show that PTH-secretion responds 
to recombinant leptin exposure in a dose dependent manner. Nude rats had positive human leptin at 2, 4, 
and 8 weeks in increasing trend for adenoma and decreasing trend for hyperplasia xenografts. Our study 
subjects included 71 (76%) Adenoma, 13 (14%) Hyperplasia, and 12 (13%) control patients. The median 
age was 59 years old of which 76% were females. This population was overweight (median BMI: 28) and 
pre-hypertensive (median SBP:131). Comparing measurements pre and post surgery, BOTH serum leptin 
and PTH levels decrease significantly in the whole cohort (p<0.001). Leptin decreases significantly in 
adenoma (p<0.001) and hyperplasia subgroups (p=0.002); it increases in controls (p=0.007). Leptin 
decrease was significantly associated with a decrease in PTH pre-post surgery (r=0.32, p=0.003) (r=0.55, 
p<.001 for adenoma subgroup). Bivariate analysis revealed several variables associated with changes in 
perioperative leptin and PTH levels. In multivariate analysis, parathyroid disease subtype, starting leptin 
levels, age, BMI, and calcium at diagnosis were significantly associated with changes in leptin. 
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Conclusion:  Our results provide interesting insight and implications into the relationship between leptin, 
obesity, and primary hyperparathyroidism (adenomas) as there is no previous research data elucidating 
the direct relationship between leptin, PTH, and the parathyroid gland. Our results provide very strong 
evidence of a new functional and physiologically relevant parathyroid hormone. Until now, no previous 
research data identified the presence of leptin hormone in parathyroid glands; it remains unclear as to 
whether high exogenous leptin levels initiate hyperparathyroid disease, possibly acting mitogenically on 
parathyroid leptin receptors, or whether hyperparathyroid glands and elevated PTH serum levels precede 
elevated leptin production, either by endogenous parathyroid production or through downstream 
endocrine signaling of adipose tissue production. Based on our results and published reports, future 
studies will test our hypothesis that leptin play a central tumorigenic role in the etiology of parathyroid 
neoplasms. 
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STATEMENT OF PURPOSE 
  
The purpose of this research project is to investigate the expression and exogenous effect of 
Leptin hormone in diseased parathyroid glands at a basic science and clinical level. Combined effects of 
low calcium and vitamin D stimulating parathyroid activity and excess PTH secretion are well 
established, especially in secondary HPTH. Unclear is the mechanism behind the development of hyper 
secreting parathyroid adenomas, responsible for nearly 90% of primary HPTH. Discovered in 1994 as a 
class 1 cytokine receptor, leptin has mounted considerable interest as a mitogenic factor involved in the 
stimulation and growth of tumors. Also, it has been implicated in multiple calcium related metabolic 
processes, which have led to numerous evaluations of the connections between vitamin-D, PTH, and 
obesity. Ultimately, these scientific findings and the prevalence of high leptin levels in patients with 
HPTH has led to our hypothesis that leptin found with increased body weight contributes to the 
pathogenesis of HPTH. 
The purpose of this thesis is to establish a direct link between high serum leptin levels in patients 
with primary hyperparathyroidism primarily through the identification of leptin hormone expression by 
parathyroid glands. Through in-situ hybridization (ISH), immunohistochemistry (IHC), 
immunofluorescence (IF), electronmicroscopy (EM), cell culture, whole organ explant experiments in 
which surgically removed human parathyroid tissue were exposed to recombinant human, and an animal 
model of parathyroid xenografts, the colocalization of leptin hormone and PTH and potential functional 
consequences and causes of parathyroid disease function are explored.  
 Lastly, the question of leptin hormone in the setting of parathyroid disease is framed within the 
broader scope of a possible etiologic mechanism for the development of primary hyperparathyroidism, 
specifically parathyroid adenomas.  
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INTRODUCTION 
 
Hyperparathyroidism is a common endocrine problem affecting as many as 1 in 500 individuals 
in the general population. A remarkably higher prevalence exists in patients that are female (four times 
more than males) and over the age of 60 (1, 2). With the recent advent of routine serum calcium 
screening, many asymptomatic individuals are now treated with minimally invasive parathyroidectomies 
and unilateral neck explorations before the development of hypercalcemic sequelae (3)—nephrolithiasis, 
pancreatitis, peptic ulcer disease, pathologic bone fractures. The combined effects of low calcium and low 
levels of Vitamin D (1,25(OH)2D3) stimulating parathyroid hyperplasia and excess secretion of 
parathyroid hormone are well established, especially in explaining the pathogenesis of secondary 
hyperparathyroidism (4). What remains shrouded in mystery is the exact mechanism behind the idiopathic 
origin of hypersecreting parathyroid adenomas, which is responsible for nearly 90% of primary 
hyperparathyroidism cases (5). Investigations into parathyroid carcinoma and multiple endocrine 
neoplasia mutations have alluded to the likelihood of tumorigenic mechanisms at play in parathyroid 
disease development including oncogenic and tumor suppressor genes and growth factors (6).  
Discovered in 1994 (7) and belonging to the class 1 cytokine receptor family (8, 9) which 
includes interleukin 6 (IL-6), granulocyte-colony stimulating factor (GCSF), glycoprotein 130 and 
leukemia inhibitory factor (LIF), the leptin hormone has mounted considerable interest as a mitogenic 
factor involved in the stimulation and growth of tumors (10-16). Physiologically, leptin is generally 
accepted as a 16.7 kDa protein translated from a 4.5 kb transcript of the Obese gene (Ob) that is 
predominantly synthesized in white adipose cells and has diverse effects on the neuroendocrine axis and 
affects appetite/satiety, regulation of long-term body weight, energy stores and starvation mainly by 
acting on the hypothalamus (17-19) (it co-localizes with STAT3 and inhibits neuropeptide mediators like 
neuropeptide Y (NPY) (20, 21) and induces proopiomelanocortin (POMC) which is processed to MSH 
and signals anorexia (20, 22-24)). The most important physiological role of leptin is as a signal switch 
between the starved and fed states-an acts as both an indicator of energy stores and a mediator of energy 
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balance through negative feedback inhibition in hypothalamus (25-27) (see Background Figure 1). The 
administration of leptin in animal models decreases food intake and increases energy expenditure. Weight 
loss occurs after leptin administration, and is restricted to adipose tissue as leptin activates lipid oxidation 
enzyme expressions and can stimulate adipocyte apoptosis and lipolysis. Leptin was once thought of as 
the anti-obesity hormone due to the prevailing view that leptin causes decreased body weight and fat 
content; patients with a congenital lack of leptin expression suffer from severe, early-onset obesity (28). 
However, the rare nature of hypoleptinemia and further research on leptin receptors have shifted the focus 
in humans away from loss of leptin and toward leptin resistance, likely due to faulty receptors, as a cause 
for obesity in humans. As a result, elevated endogenous plasma leptin levels don’t always prevent obesity 
but rather are more commonly indicative of leptin resistance and dysfunction of the feedback regulatory 
loop—resulting in a leptin-deficient phenotype (29, 30).  
Circulating serum levels of leptin positively correlate with body mass index (BMI) as well as 
mRNA transcripts and protein in white adipose tissue. Leptin is continuously secreted but appears to be 
influenced predominantly by fat energy stores although additional stimulus may play a role including 
inflammatory cytokines (8, 9, 23, 31, 32).  Furthermore, levels appear to be sexually dimorphic, where 
women have higher levels than men after controlling for body fat, sex hormones, and glucose tolerance. 
Taken altogether, greater adiposity, female gender—premenopausal women have higher leptin levels than 
postmenopausal women—and insulinemia are significant determinants of leptin concentration in humans 
(33, 34). An additional study looking at hemodialysis patients confirm the sexual dimorphism favoring 
increased leptin levels in females (4:1 ratio female to male) but found no significant differences between 
diabetic and non-diabetic patients (35). Leptin acts through its receptor (Ob-R), where of multiple 
alternative splice products (27, 36-40), only the long receptor isoform composed of not only the 
extracellular ligand-binding domain, a single transmembrane domain, but also a intracellular signaling 
domain critical for function and interactions with the janus kinase signal transducers and activators of 
transcription (JAK-STAT3), phosphoinosityl-3 kinase (PI3K), mammalian target of rapamycin (mTOR), 
and 5' AMP-activated protein kinase (AMPK) intracellular pathways (23, 41, 42) (see Background Figure 
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2 and 3). Both leptin and its long receptor isoform production have been found in extra-adipose, such as 
the kidneys which express the leptin receptor short isoform which possibly functions in serum leptin 
clearance (43), and hypothalamic tissues (the site of highest LRb expression (20, 44))——leading to 
leptin’s emergence as a master hormone involved in pleiotropic bodily functions and organs including the 
neuroendocrine, cardiovascular, skeletal, metabolic/glucose tolerance, reproductive, hematopoietic and 
immune systems (9, 34, 45-61). Furthermore, leptin has become increasingly implicit in multiple calcium 
related metabolic processes.  
Recently, leptin has been shown to affect bone mass in a dual manner; local administration to the 
hypothalamus results in indirect suppression of osteoblasts via independent sympathetic autonomic 
nervous (20, 62) and serotonin dependent systems, while systemic administration leads to PTH-like 
oestrogenic bone formation (21, 63-66). Remarkably, leptin levels are higher in premenopausal women 
(67) and correlates with increased bone mineral densities (BMD) in the early postmenopausal state (68). 
The emergence of leptin’s correlation with BMD (67, 69) and already established correlation with BMI 
emphasizes further its potential role in bone formation may mechanistically explain why BMI has been 
traditionally associated with higher BMD and as being osteoprotective. Additionally, leptin appears to 
have a direct affect on endovascular tissue as well as through sympathetic activation leading to obesity-
related vascular calcification and hypertension, respectively (70-73). This connection between adipocytes 
and endothelial cells is further supported by in vitro studies that have shown leptin hormone stimulates 
endothelin-1 expression, a potent mitogen and vasoconstrictor, in endothelial cells (74, 75), and when 
over expressed mediates vascular smooth muscle cell calcification (76). Additionally, leptin stimulates 
both proliferation and migration of vascular smooth muscle cells via increased mitogen-activated protein 
(MAP) kinases and phosphatidylinositol (PI) 3-kinase activity (77). These studies essentially implicate 
leptin in obesity-related diseases, which involve the formation and development of vascular lesions like 
hypertension and atherosclerosis (78-81). 
Leptin’s osteogenic connections have led to numerous investigations showing associations 
between vitamin D, parathyroid hormone (PTH), and obesity. Matsunuma et al found that leptin 
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administration in leptin deficient (Ob/Ob) mice decreases renal vitamin D overexpression, which 
indirectly increases circulating levels of PTH via an endocrine feedback mechanism (82). The reverse 
relationship in which vitamin D administration was found to be associated with decreased leptin was 
found to be true by Menendez et al (83). In women, Maetani et al were able to confirm the positive 
correlation between leptin and PTH levels and their inverse relationship with vitamin D. This relationship 
held strongest when vitamin D levels were consistent with clinical values associated with the 
hyperparathyroid state (84). In a study looking at patients with clinical hyperparathyroidism, leptin serum 
levels were found to be significantly increased compared to healthy subjects controls. Taken together, 
comorbid parathyroid disease and obesity was associated with even greater serum leptin levels than in 
settings of either disease alone (85). Leptin is primarily cleared by the kidneys and has a half-life of about 
25 minutes, which is the same for both obese and normal weight patients (86). As a result, patients with 
chronic kidney disease who routinely develop secondary parathyroid disease have quite elevated leptin 
levels compared to normal controls due to poor renal clearance (32, 35, 87-91). Although leptin levels are 
elevated, leptin receptor levels do not differ from controls implicating that free, bioactive leptin is likely 
elevated. The rate of reduction in serum leptin levels after dialysis with polysulfone membrane dialyzers 
(PS-N and PS-UW) are greater than cellulose membrane dialyzers (35). A study evaluating leptin levels 
in renal failure patients found that those on peritoneal dialysis (CAPD and APD same) had significantly 
higher values than patients receiving conservative therapy or hemodialysis, with those on hemodialysis 
patients having the lowest leptin serum levels (87). They further confirm that this difference is explained 
by female gender and obesity (and insulin resistance) as predictors of increased leptin levels. 
A meta analysis found an increased prevalence of obesity and higher BMI values among patients 
with hyperparathyroidism compared to their normal counterparts (92); conversely, PTH levels have been 
consistently found to correlate positively with BMI across studies (93, 94). Remarkably, the diurnal 
rhythms of leptin and PTH secretion and their serum level patterns are intricately tied; both have identical 
mid-morning nadirs and peaks at 1-3 AM that are independent of an endogenous circadian clock. Leptin 
has been implicated in the control of other pulsatile endocrine systems (20, 95-97). For example, leptin 
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interacts with the hypothalamic-pituitary-adrenal axis and its various components by regulating CRH 
synthesis and secretion as well as interfering with ACTH and corticosterone secretion during animal 
stress response (98, 99). Although some studies show an association between leptin deficiency and 
thyroid dysfunction (19, 28, 100), multiple studies have discordant conclusions (101).  
Ultimately, these scientific associations (see Background Figure 4) and the epidemiologic 
prevalence of higher leptin levels (33, 102) and development of hyperparathyroidism in women have led 
to the formation of a critical hypothesis: could higher leptin values found with increased body weight 
contribute to the pathogenesis of hyperparathyroidism through a mitogenic effect (103).  We pursued the 
hypothesis that leptin hormone directly interacts with the parathyroid gland and influences parathyroid 
neoplasm PTH secretion. Although leptin expression has been found in numerous other tissue types 
(placenta, skeletal muscle, mammary epithelium, and gastric fundus mucosa (104-108) the parathyroid 
gland has never been explored. We present the first study of its kind to reveal the biochemical expression 
of leptin and leptin receptor in parathyroid gland tissue of patients with hyperparathyroidism while also 
showing that exogenous leptin exposure to these parathyroid neoplasms results in increased PTH 
secretion.  
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Summary of Findings 
 
• Leptin is expressed in parathyroid glands at the mRNA and protein level 
o Parathyroid hyperplasia expresses leptin at greater quantities than adenoma 
o Verified by in-situ hybridization, immunohistochemistry, immunofluorescence, 
immuno electron microscopy 
• Leptin does not colocalize with PTH secretory granules intracellularly in 
parathyroid secretory chief cells, but does colocalize near the cell membrane 
o Verified by in-situ hybridization, immunohistochemistry, immunofluorescence, 
immune-electron microscopy 
• Leptin influences PTH secretion in a dose dependent manner in explanted 
parathyroid tissue 
o AG490 inhibition appears to abrogate such effects, especially in the presence of 
high leptin conditions (100 ng/mL) 
o LY294002 inhibition was not found to have abrogating effects on PTH secretion 
in the presence of leptin exposure 
• Leptin is secreted into systemic circulation 
o Xenografts of parathyroid tissue into nude rats subsequently revealed positive 
levels of human leptin hormone 
o Xenografts of parathyroid tissue into Ob/Ob mice subsequently revealed 
excessive weight loss and leptin induced symptoms 
• Serum Leptin levels decrease perioperatively after diseased parathyroid glands are 
surgically removed 
o Median decrease in adenoma patients’ leptin levels of 2.6 ng/mL 
o Median decrease in hyperplasia patients’ leptin levels of 4.3 ng/mL 
o Median increase in control hemithyroid patients’ leptin levels of 1.9 ng/mL 
• Parathyroid Hormone 1-84 amino acid stimulates leptin release from adipose tissue 
explants 
o No significant leptin hormone release was found with exposure to parathyroid 
hormone 1-34 amino acid length and isoproterenol 
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Background Figures (1-4) 
 
Figure 1: The Physiological Role of Leptin 
Leptin primarily acts in an endocrine feedback loop to maintain homeostasis of a range of metabolic and 
endocrine processes—such as weight control, body fat and energy stores. A greater amount of adipose 
tissue results in an increase in leptin secretion, resulting in net energy expenditure exceeding food intake. 
When adipose tissue stores decrease, leptin levels decrease resulting in a positive energy balance where 
food intake exceeds energy expenditure. The hypothalamus plays a central role in these responses 
mediated by neuropeptides such as melanocortin-4 (MC-4), MSH, ART, NPY GnRH, and GHRH (27). 
Image removed in consideration of US Copyright Law 
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Figure 2: Leptin Receptor Signaling 
 
Leptin is expressed from the obese (ob) gene and predominantly produced in white adipose tissue. The 
leptin receptor (Ob-R) is part of the class 1 cytokine receptor super family and undergoes alternate gene 
splicing and generates six leptin receptor isoforms. The long Ob-Rb isoform plays a crucial role in 
regulating obesity. High levels of Ob-Rb have been found primarily in the hypothalamus where leptin 
action mainly occurs (109). Long isoform Leptin receptor activation influences STAT3 tyrosine 
phosphorylation in vivo and acts as a potent activator of JAK/STAT signaling (30). The Leptin signaling 
pathway is blocked by SOCS-3 (suppressors of cytokine signaling-3) and by protein tyrosine phosphatase 
1B (PTP-1B) dephosphorylation. Leptin receptor activation also stimulates additional signaling pathways 
downstream of JAK, including PI3K (phosphotidylinositol 3-kinase) and MAPK (Ras-mitogen activated 
protein kinase). Once the long isoform Leptin receptor binds Leptin, JAK2 phosphorylates two conserved 
C-terminal tyrosine residues: Tyr-986 phosphorylation is required for binding and activation of PTPN11, 
ERK/FOS and interaction with SOCS3. Tyr-1141 phosphorylation is required for STAT3 activity. 
 
Image removed in consideration of US Copyright Law 
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Figure 3: Jak2/Stat3 of the Leptin Receptor Pathway 
 
 
Leptin binding to the extracellular domain of the leptin receptor long isoform (LRb) mediates the activation 
of the intracellular LRb-associated Jak2 tyrosine kinase, resulting in autophosphorylation on tyrosine 
residues (pY) as well as the phosphorylation of Y985, Y1077, and Y1138 residues on the intracellular tail 
Phosphorylated Y1138 recruits STAT3 (signal transducer and activator of transcription), which mediates 
transcriptional events, such as the transcription of the SOCS3 (inhibitory suppressor of cytokine 
signaling). Phosphorylated Y1077 recruits and facilitates the transcriptional activation of STAT5. 
Phosphorylated Y985 recruits SHP-2 and also binds to SOCS3 and mediates feedback inhibition of LRb 
signaling (dotted lines). The tyrosine phosphatase PTP1B, although not regulated by leptin in this 
manner, also inhibits LRb/Jak2 signaling. The cellular mechanisms by which LRb couples to the 
regulation of phosphatidylinositol 3-kinase (PI3K), mammalian target of rapamycin (mTOR), and AMP-
activated protein kinase (AMPK) pathways remain unclear (23). 
Image removed in consideration of US Copyright Law 
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Figure 4:  Clinical Associations between Obesity, Hyperparathyroidism, and Chronic 
Renal Insufficiency 
 
 
Ultimately, these scientific associations and the epidemiologic prevalence of higher leptin levels and 
development of hyperparathyroidism in women have led to the formation of a critical hypothesis: could 
higher leptin values found with increased body weight contribute to the pathogenesis of 
hyperparathyroidism through a mitogenic effect. Based on the previously mentioned data, we pursued the 
hypothesis that leptin hormone directly interacts with the parathyroid gland and influences parathyroid 
neoplasm function. 
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METHODS and MATERIALS 
 
Patients  
Over a one-year period we enrolled 96 patients in a prospective study of leptin and 
hyperparathyroidism (see Methods and Materials Figure 1). All patients gave informed consent in 
accordance with an approved HIC protocol (#1005006788) by the Institutional Review Board of Yale 
University School of Medicine. The patients were enrolled based on their diagnosis of 
hyperparathyroidism (including primary, secondary or tertiary hyperparathyroidism) and their candidacy 
for surgical intervention (including minimally invasive parathyroidectomy and bilateral neck exploration).  
Patient demographic and clinical information (see Results Table 1) were recorded if available 
including patient age, gender, calculated body mass index, bone mineral density reports, medical history, 
radiographic imaging results, pre-surgery basic clinical laboratory values, surgical parathyroid specimen 
pathology reports, and intraoperative PTH values. Furthermore, parathyroid tissue collection occurred as 
follows. 
Tissue Specimen Collection 
 In sterile fashion, typically between 100 to 300 mg of adenoma or hyperplastic parathyroid tissue 
from hyperparathyroid patients was dissected directly with a surgical knife on the operative stage after 
trimming visible fat and connective tissue surrounding the glands and prepared according to the 
requirements of the following analyses. 
In-Situ Hybridization 
Tissues were flash frozen in liquid nitrogen and stored at -80 C before serial 5 um sections were 
mounted on FisherBrand Plus gelatin-coated slides and post-fixed in Phylogeny Preservation Medium No. 
4.  Two sections of each sample were mounted on each slide. The sections were rehydrated in a series of 
ethanols and PBS, digested with proteinase K, treated with triethanolamine/acetic anhydride, washed and 
dehydrated. cRNA probe transcripts were synthesized in vitro according to manufacturer’s conditions 
(Ambion) and labeled with 35S-UTP (>1000 Ci/mmol; Amersham). These cRNA probes were made from 
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exon-specific cDNA created from RT-PCR and primers that covered the base pairs 46-579 (NM_00230.1) 
for leptin and bp 3052-3611 (NM_002303.3) for the longest isoform of the leptin receptor) (see Material 
and Methods Table 1). Sections were hybridized overnight at 55°C in 50% deionized formamide, 0.3 M 
NaCl, 20mM Tris-HCl pH 7.4, 5 mM EDTA, 10 mM NaH2PO4, 10% dextran sulphate, 1 x Denhardt’s, 50 
µg/ml total yeast RNA, and 50-80,000 cpm/µl 35S-labeled cRNA probe.  The tissue was subjected to 
stringent washing at 65°C in 50% formamide, 2 x SSC, 10 mM DTT and washed in PBS before treatment 
with 20 µg/ml RNAse A at 37°C for 30 minutes. Following washes in 2 x SSC and 0.1 x SSC for 10 
minutes at 37°C, the slides were dehydrated, then dipped in Kodak NTB nuclear track emulsion and 
exposed for 1 to 3 weeks in light-tight boxes with desiccant at 4°C. Photographic development was 
carried out in Kodak D-19. Slides were counterstained lightly with hematoxylin and eosin and analyzed 
using phase contrast and darkfield optics.  Sense control cRNA probes (identical to the mRNAs) always 
gave background levels of hybridization signal. The RNA content of the parathyroid tissue has been 
validated using a human von Willebrand factor. The results were best viewed with darkfield illumination, 
but with a 20x or 40x phase-contrast objective, the silver grains can be localized over particular cells. The 
antisense probe (AS) detected the mRNA and the sense control probe (S) shows the background level of 
silver grains for the experiments.   
Immunohistochemistry 
Reagents: leptin (Ob (A-20), Santa Cruz Biotechnology, Santa Cruz, CA, cat# sc-842), leptin 
receptor (Ob-R (H-300), Santa Cruz Biotechnology, Santa Cruz, CA, cat# sc-8325), parathyroid hormone 
(BGN/1F8, Abcam, Cambridge, MA, cat# ab63993) DAKO dual endogenous enzyme block (S2003, 
DAKO, Carpinteria, CA), DAKO antibody diluent (S0809, DAKO, Carpinteria, CA), DAKO LSAB2 
(K0675, DAKO, Carpinteria, CA), DAKO DAB (K3468, DAKO, Carpinteria, CA), Liquid Permanent 
Red Chromogen (K0640, DAKO, Carpinteria, CA), TBS/tween pH 7.2 (#S2736-5GL, Poly Scientific, 
Bayshore, NY), HIER DAKO TRS (#S1699, DAKO, Carpinteria, CA). 
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Table 1: In-Situ Hybridization Primers Developed for Leptin and Leptin Receptor 
Gene Target Primers 
Leptin* F 5’ TGGGAAGGAAAATGCATTGGG 3’   
F 5’ AAGAGTGACCTTCAAGGCCTCA 3’  
Long Isoform Leptin Receptor+ 
F5’  GGGTTCTGTTTGTATTAGTGACC 3’ 
F 5’ TCTTCTTACTAGAAGTTCCAAGTTG 3’ 
 
ATG and TGA of the ORF are underlined 
*Primers were chosen to 5’ and 3’ ends of the human leptin open reading frame (ORF). A full length cDNA 
containing the leptin ORF was obtained from Origene, but this clone contained an RNA polymerase start site at the 
5’ end only. So it was necessary to subclone the ORF into a riboprobe vector such as pGEMT Easy (Promega). 0.1 
nanograms of this cDNA was used in a PCR reaction that included Promega 1x buffer B, 0.2 mM dNTPs, 0.8 uM 
primers, 2.5 U Taq polymerase (Promega). The cDNA was amplified for 30 cycles at an annealing temperature of 62 
degrees, run on a 1% agarose gel and excised for extraction with Qiaex II (Qiagen). These primers yielded a PCR 
fragment of 534 bp that was ligated into pGEMT Easy (Promega). Two clones were picked following transformation 
into JM109 (Promega). These clones were miniprepped and sequenced. One was chosen based on its sequence and 
BLAST comparison. The probe consists of 534 nucleotides and is specific for the human leptin ORF, 11 nucleotides 
of 5’ Untranslated Region (UTR) and 19 nucleotides of 3’UTR. 
+ One microgram of human brain total RNA (Stratagene) was reverse transcribed using random hexamers (Promega) 
and Superscript II (Invitrogen) for one hour at 37 degrees. This cDNA was suspended in a total volume of 100 
microliters. Five microliters of this cDNA was used in a PCR reaction that included Promega 1x buffer B, 0.2 mM 
dNTPs, 0.8 uM primers, 2.5 U Taq polymerase (Promega) . The cDNA was amplified for 30 cycles at an annealing 
temperature of 62 degrees, run on a 1% agarose gel and excised for extraction with Qiaex II (Qiagen). These primers 
yielded a PCR fragment of 560 bp that was ligated into pGEMT Easy (Promega). Two clones were picked following 
transformation into JM109 (Promega). These clones were miniprepped and sequenced. One was chosen based on its 
sequence and BLAST comparison. The probe consists of 560 nucleotides and is specific for the human leptin 
receptor long isoform exon, Genbank access AC097063.2, Homo sapiens chromosome 1, clone RP11-430H12  
 
Human tissues taken from the operative room were immediately placed in liquid nitrogen before 
serial frozen sections were made. The fresh frozen blocks were sectioned at 5um. The slides were dried 
and then deparaffinized and rehydrated through histological grade xylene, ethanol and distilled water. The 
slides were then placed in HIER DAKO TRS (#S1699, DAKO, Carpinteria, CA) for antigen unmasking 
at 98 (+/-3) deg C for 30 minutes then cooled to room temperature. The slides were then rinsed in distilled 
water, then soaked in tris-buffered saline (TBS) for 5 min, and followed by DAKO dual endogenous 
enzyme block (S2003, DAKO, Carpinteria, CA) for 5 min to block nonspecific antibody binding, then 
rinsed once again with distilled water and TBS (#S2736-5GL, Poly Scientific, Bayshore, NY). 
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Immunohistochemistry was performed with a DAKO Autostainer (DAKO, Carpinteria, CA, 
USA) for the purpose of dual staining of leptin or leptin receptor and PTH.  The sections were then 
incubated with a cocktail of primary antibodies: leptin (Ob (A-20), Santa Cruz Biotechnology, Santa 
Cruz, CA, cat# sc-842) or leptin receptor (Ob-R (H-300), Santa Cruz Biotechnology, Santa Cruz, CA, 
cat# sc-8325) and parathyroid hormone (BGN/1F8, Abcam, Cambridge, MA, cat# ab63993) under the 
manufacturer’s recommended dilutions with DAKO antibody diluent (S0809, DAKO, Carpinteria, CA) 
for 15 minutes. They were then rinsed and incubated with a mixture of horseradish peroxidase conjugated 
anti-mouse IgG1 [DAKO LSAB2 (K0675, DAKO, Carpinteria, CA)] and alkaline phosphatase conjugated 
anti-rabbit IgG. Antibodies were visualized with DAKO DAB (K3468, DAKO, Carpinteria, CA) and 
Liquid Permanent Red Chromogen (K0640, DAKO, Carpinteria, CA) as chromogens, respectively. After 
immunostaining, the sections were lightly counterstained with hematoxylin, dehydrated clear and 
mounted.  
Immunofluorescence Conventional Fluorescent Microscopy 
Human tissues taken from the operative room were immediately stored in 4% paraformaldehyde 
at room temperature before paraffin blocks were made. The paraffin blocks were sectioned at 5um. The 
slides were dried then deparaffinized and rehydrated to distilled water. The slides were then placed in 
citrate buffer at 98 (+/-3) deg C for 30 minutes then cooled to room temperature. The slides were then 
rinsed in distilled water, then soaked in tris-buffered saline (TBS) for 5 min. Dual staining was achieved 
by applying a combination of primary antibodies to leptin (Ob (A-20), Santa Cruz Biotechnology, Santa 
Cruz, CA, cat# sc-842) or leptin receptor (Ob-R (H-300), Santa Cruz Biotechnology, Santa Cruz, CA, 
cat# sc-8325) and parathyroid hormone (BGN/1F8, Abcam, Cambridge, MA, cat# ab63993) under the 
manufacturer’s recommended dilutions for 1 hour then rinsed in TBS. After, DyLight 649 and DyLight 
488 (Thermo Fischer Scientific, Rockford, IL, cat# ab96894 and ab96879) conjugated secondary 
antibodies specific to the species of the primary antibody, respectively, were applied for 30 min. The 
slides were rinsed in TBS; DAPI was used to visualize the nuclei and the sections were cover slipped in 
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aqueous mounting media for conventional fluorescent microscopy and image acquisition was performed 
using an Olympus BX61 microscope with 40X/0.95 and 60X/1.25 objectives at room temperature and 
captured through an Olympus DP71 digital camera using Olympus MicroSuite imaging software. 
Brightfield images were visualized using 4X/0.16, 10X/0.40, 20X/0.75, 40x/0.95, and 60X/1.25 
objectives at room temperature using the same microscope and digital camera. 
Immuno Electron Microscopy 
Tissue was immediately fixed in 4% paraformaldehyde/0.1% gluteraldehyde in phosphate 
buffered saline, then placed in 2.3M sucrose overnight at 4C on a rotor. These were frozen rapidly onto 
aluminum pins in liquid nitrogen. The frozen block was trimmed on a Leica Cryo-EMUC6 UltraCut and 
70nm thick sections were collected using the Tokoyasu method (110). The sections were collected, 
thawed and placed on a nickel formvar/carbon coated grid floated in a dish of PBS ready for 
immunolabeling. 
Immunolabeling of sections occurred as follows. Grids were placed section side down on drops of 
0.1M ammonium chloride to quench untreated aldehyde groups, then blocked for nonspecific binding on 
1% fish skin gelatin in PBS for 20 minutes. Single labeled Grids were incubated on either a primary 
rabbit anti-Leptin (Ob (A-20), Santa Cruz Biotechnology, Santa Cruz, CA, cat# sc-842) 1:25 or mouse 
anti-PTH(BGN/1F8, Abcam, Cambridge, MA, cat# ab63993) 1:50 for 30mins, rabbit anti-mouse bridge 
(JacksonImmuno) was used at 1:200. Grids were rinsed and placed on protein A gold 10nm 
(UtrechtUMC) for 30 minutes, fixed using 1% gluteraldehyde, then rinsed and transferred to a 
UA/methylcellulose drop for 10 minutes, then collected and dried before imaging. 
Double-labeled grids used 10nm PAG with the Leptin and 5nm PAG with the PTH. Samples 
were viewed FEI Tencai Biotwin TEM at 80Kv. Images were taken using Morada CCD and iTEM 
(Olympus) software.  
Parathyroid Cell Culture 
All materials prepared and techniques used are as described per Hellman (111). Tissues were 
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immediately brought to the laboratory in ice-cold transport buffer (HEPES-buffered Ham’s F10 with 10% 
fetal calf serum (FCS), 100 U/ml penicillin, and 100 g/ml streptomycin). Subsequently, the glands are 
minced with sharp Iris scissors and digested in 10 mL (per approx 100 mg minced tissue) of 1 mg/mL 
collagenase, 0.05 mg/mL DNase, 1.5% BSA, and 1.25 mM Ca2+ in Ham’s F10 HEPES buffered medium 
at 37°C on a shaking incubator at 300 rpm for 20–30 min. The cell suspension was washed two times 
with transport buffer to inactivate and dilute the collagenase. Dead cells and debris are removed by 
centrifugation (5 min; 300g) through 25% standard isotonic Percoll diluted in PBS. The suspensions are 
thoroughly washed with PBS twice and plated on culture dishes in culture media (Dulbecco’s minimal 
essential medium supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, 100 g/ml 
streptomycin, 5 ng/mL EGF and 50 µg/mL bovine pituitary extract). The entire procedure generally yields 
small clusters of 2–20 cells, which were subsequently used for immunofluorescence studies. PTH levels 
from cell culture medium was measured in duplicate according to the manufacturer’s directions utilizing 
an immunoradiometric assay, specifically Total Intact PTH Assay (Scantibodies Laboratory Inc, Santee, 
CA, cat# 3KG013) in order to assess PTH secretion as a marker for cell viability and function. 
Immunofluorescence under Confocal Spinning Disc Microscopy  
Cells were grown on glass-bottom dishes coated with poly-lysine (Mattek), washed twice with 
PBS, and fixed with 4% PFA for 15 min.  After fixation cells were washed three times with 
PBS/0.05%Tween20 (PBS-T), and incubated for 15 min. with 5%BSA/PBS-T,washed and incubated for 
one hour at RT with a 1/200 dilution of rabbit polyclonal antibody against Leptin prepared in 
5%BSA/PBS-T buffer (Ob (A-20), Santa Cruz Biotechnology, Santa Cruz, CA, cat# sc-842). Next cells 
were washed three times for 5 min. with PBS-T and incubated with a 1/300 dilution of a secondary 
antibody labeled with Dylight488 (donkey anti-rabbit; Jackson ImmunoResearch, West Grove, PA; cat# 
711-485-152), plus phalloidin-Alexa568 (Invitrogen, Eugene, OR; cat#A12380), and 2.5ug/mL Hoechst 
33342 (Invitrogen, Eugene, OR; cat#H3570) in 5%BSA/PBS-T, incubated for 30 min. at RT, washed, and 
a drop of anti-fade ProLong gold reagent was added (Invitrogen, Eugene, OR; cat#P36934).  To seal the 
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sample a 12mm diameter cover-slip was placed inside the 14mm-diameter grove of the glass-bottom dish, 
and incubated at RT over-night for the anti-fade reagent to cure.  Samples were imaged with a 60X, 1.4 
NA objective on an inverted microscope (Olympus IX81) fitted with an ‘Ultra-View’  (Perkin-Elmer) 
spinning disc confocal fluorescence illumination.  Samples were illuminated with laser lines at 405nm, 
488nm and 568nm laser lines to be able to excite the Hoechst, Dylight488, and phalloidin-568 fluorescent 
molecules, respectively and imaged on a 1Kx1K EMCCD camera (Hamamatsu Photonics). 
Leptin protein was prepared, labeled, and conjugated with Alexa 488 according to the 
manufacturer’s protocol (Alexa Fluor ® 488 Microscale Protein Labeling Kit (A30006), Invitrogen, 
Carlsbad, CA) for leptin uptake experiments in cultured parathyroid cells. 
Parathyroid Tissue Explant Experiments and Culture Medium PTH Analysis  
Parathyroid tissues were brought to the laboratory in ice-cold transport buffer. The explants were 
dissected into small pieces (2 x 2 x 2 mm) and placed into one well of a six-well plate containing 6 mL of 
a standard HEPES buffered solution (58.44 M NaCl, 74.55 M KCl, 147.02 M CaCl2H2O, 246.48 M 
MgSO47H2O, 141.98 M NaH2PO4, 238.3 M HEPES, 180.2 M glucose) and allowed to incubate at 37C for 
2 hours. Subsequently, 500 ul aliquot of the solution bathing the explant was removed and stored at -80C, 
to ensure each explant piece had similar functional PTH secretory capacity. Each well was then replaced 
with pre-warmed to 37C standard HEPES buffered solution with a final concentration of 0, 5, or 100 
ng/mL recombinant human leptin (Ob (hBA-147), Santa Cruz Biotechnology, Santa Cruz, CA, cat# sc-
4912). A negative control condition in which explants were exposed to 10ng/mL blocking peptide for 
anti-Leptin antibody (Ob-A 20 P, Santa Cruz Biotechnology, Santa Cruz, CA, cat# sc-842) was utilized as 
well. Subsequently, serial collections of 500 ul aliquot of each of the aforementioned conditions at 10, 25, 
100, 250, at 500 minutes and again stored at -80C. Each well was replaced again with new standard 
HEPES buffered solution with the same previous concentration of recombinant human leptin and serial 
collections made at 10, 25, and 100 minutes. PTH levels recorded as radioimmunoassay counts per 
minute (CPM) from the collected explant solutions were measured in duplicate according to the 
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manufacturer’s directions utilizing an immunoradiometric assay, specifically Total Intact PTH Assay 
(Scantibodies Laboratory Inc, Santee, CA, cat# 3KG013) in order to look for changes in PTH secretion 
based on leptin hormone exposure. 
Different experimental conditions were also applied to the explants in which the above mentioned 
protocol was modified such that the parathyroid explant tissues were incubated initially for two hours at 
37C in Standard Hepes with one of the following conditions 0.625mM AG490 (a JAK2/STAT3 inhibitor 
from EMD Chemicals, Gibbstown, USA), 100uM Ly294002 (a phosphatidylinositol 3-kinase (PI3K) 
inhibitor from Cayman Chemical, Ann Arbor, MI), Ob-R H-300 (a C-terminus anti-Leptin receptor 
antibody from Santa Cruz Biotechnology, Santa Cruz, CA), or LPR-02 (an N-terminus anti- Leptin 
receptor antibody from Abcam, Cambridge, MA). After incubation in these conditions, the explants were 
exposed to human recombinant Leptin protein as described previously. 
Parathyroid Xenograft in Nude Rat Model  
Tissues were immediately brought to the laboratory in ice-cold transport buffer as above. Under 
IACUC approval and protocol #2010-11412, a Rowett nude rat (Charles River Laboratories International, 
Inc, Wilmington, MA) xenograft model of parathyroid adenoma and hyperplasia was developed in which 
primary specimens obtained from 4 patients (3 with parathyroid adenoma and 1 with hyperplasia) 
undergoing surgical resection were implanted submuscularly on the dorsum of the immunocompromised 
rats as small (<2 mm) pieces of tumor. Blood was collected at 1, 2, and 4 weeks after xenograft 
transplantation (see Methods and Materials Figure 2). The blood was centrifuged and serum was collected 
and stored at -80C. Serum was then analyzed and quantified for human and rat leptin serum levels using 
the Sensitive Human Leptin Radioimmunoassay (RIA) kit (LINCO Research, St. Charles, MO, cat# SHL-
81K) and Rat Leptin RIA kit (LINCO Research, St. Charles, MO, cat# RL-83K), respectively. The rats 
were eventually sacrificed and transplanted parathyroid tissue were excised and sent for histological H&E 
staining by standard convention to assess for tissue viability. 
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Blood Specimen Collection  
All study subjects had blood collections at four time points based on clinic and operative 
logistics: time point 1) one to two months prior to surgery as a pre-operative baseline, time point 2) 15 
minutes to one hour prior to surgery as a perioperative baseline, time point 3) one hour after surgery to 
assess perioperative changes, time point 4) three to four weeks after surgery as a new postoperative 
baseline. A volume of 10 mL of blood was collected by peripheral venipuncture at each of the described 
time points in BD Vacutainers blood collection tubes and then immediately centrifuged. Serum was 
separated from blood cells and stored in 1 mL aliquots at -80◦C for analysis.  
Serum Leptin Hormone and PTH Analyses  
Leptin serum levels were measured in duplicate according to the manufacturer’s directions 
utilizing the Sensitive Human Leptin Radioimmunoassay (RIA) kit (LINCO Research, St. Charles, MO, 
cat# SHL-81K).  
Routine PTH measurements were made at the same time points as leptin as part of routine patient 
clinical care. 
Adipose Tissue Explant Experiments and Culture Medium Leptin Hormone Analysis 
Adipose tissues were brought directly from the operative field from abdominoplasty patients to 
the laboratory in ice-cold transport buffer. The explants were dissected into small pieces (5 x 5 x 5 mm) 
and placed into one well of a six-well plate containing 6 mL of a standard HEPES buffered solution 
(58.44 M NaCl, 74.55 M KCl, 147.02 M CaCl2H2O, 246.48 M MgSO47H2O, 141.98 M NaH2PO4, 
238.3 M HEPES, 180.2 M glucose) and allowed toincubate at 37C for 2 hours. Subsequently, 500 ul 
aliquot of the solution bathing the explant was removed and stored at -80C, to ensure each explant piece 
had similar functional leptin hormone secretory capacity. Subsequently, each well was then replaced with 
pre-warmed to 37C standard HEPES buffered solution with a final concentration of 0 or 300 pg/mL 
recombinant parathyroid hormone-84 amino acids (Parathyroid Hormone 1-84, Peptides International Inc, 
Louisville, KY, cat# PTH-4134-v) or 34 amino acids (Parathyroid Hormone 1-34, EMD Millipore, 
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Philadelphia, PA, cat# 05-23-5501-1MG) in length, or isoproterenol HCL (EMD Millipore, Philadelphia, 
PA, cat#420355) in 0 or 1uM. Subsequently, serial collections of 500 ul aliquot of each of the 
aforementioned conditions at 6, 12, and 24 hours were again stored at -80C. Each experimental condition 
was performed in triplicate. Leptin serum levels were measured in each of the samples collected in 
duplicate according to the manufacturer’s directions utilizing the Sensitive Human Leptin 
Radioimmunoassay (RIA) kit (LINCO Research, St. Charles, MO, cat# SHL-81K). 
Statistical Analysis  
Due to the non-normality of Leptin and PTH values, Wilcoxon signed-rank test, the non-
parametric version of paired t-test, was used to compare hormone levels measured at different time points 
(time point 1 vs. 4 and time point 2 vs. 3). ANCOVA model was used to compare the perioperative 
change of Leptin (time point 2 and 3) between control and disease group while adjusting for pre-surgery 
level (measurement at time point 2).  
Pearson correlation was calculated between the absolute perioperative changes in Leptin and PTH 
(112, 113). Analysis of within-subject correlation was carried out to investigate if the decrease in Leptin 
was associated with a decrease in PTH within the same individual by removing the difference between 
subjects.  
For the parathyroid explant experiments and PTH secretion measurements a mixed model 
approach involving repeated ANOVA was used to take into consideration the correlation between 
repeated measurements. All the analyses were performed using SAS 9.2 (Cary, NC). 
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Methods and Materials Figures (1-2) 
Figure 1: Patient Enrollment and Experiment Flowchart 
 
 
 
Figure 2: Experiment Flowchart: Parathyroid Xenograft in Rowett Nude Rat Model 
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RESULTS 
Patient Clinical Characteristics 
The results of demographic, biochemical, and hemodynamic parameter calculations in all groups 
were collected (see Results Table 1). Ninety-six subjects were involved in the analysis; these subjects 
included 71 (76%) Adenoma, 13 (14%) Hyperplasia, and 12 (13%) controls. The median age was 59 
years old (range 24 – 85) with more patients being female (76%). This population was overweight with 
median BMI of 28 (range 17 – 58), and pre-hypertensive with median SBP of 131 (range 102-186) 
mmHg. 
Table 1: Patient Clinical Characteristics 
 N (%)* 
Gender  
Female 73 (76) 
Male 23 (24) 
Age (yrs) 59 (24, 85) 
SBP 131 (102, 186) 
DBP 79 (50, 109) 
BMI 28 (17, 58) 
Calcium at diagnosis (mg/dL) 11 (8, 12) 
Vitamin D 25-OH at diagnosis (ng/mL) 28 (5, 77) 
BMD status  
Normal 30 (31) 
Osteopenia 28 (29) 
Osteoporosis 27 (28) 
Fosamax or Sensipar Use  
Yes 15 (16) 
No 78 (81) 
Parathyroid Disease Subtype  
Adenoma 71 (74) 
Control Hemithyroid 12 (13) 
Hyperplasia 13 (13) 
Total Parathyroid Weight Removed (mg) 374 (35, 14190) 
Spect Sestamibi Localization  
Yes 62 (65) 
No 14 (15) 
Parathyroid gland removed  
L-inferior only 18 (19) 
L-superior only 20 (21) 
R-inferior only 20 (21) 
R-superior only 3    (3) 
Other 35 (36) 
* Data presented as n (%) for categorical variables, median (min, max) for continuous variables.  
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In-Situ Hybridization 
Below are the results of a validation study of human parathyroid mRNA content by in situ 
hybridization (ISH) study of the expression of human von Willebrand Factor (vWF) and human 
parathyroid hormone (PTH) mRNA in human parathyroid tissue. Samples included a normal parathyroid 
(see Results Figure 1), a parathyroid adenoma (see Results Figure 2), and a hyperplastic parathyroid (see 
Results Figure 3), all of which contained PTH mRNA at high abundance expressed in chief cells. The 
endothelial cells in the capillaries and venules expressed vWF at a moderate to low level. The assay result 
validated the RNA content of each of the tissues making the tissues suitable for hybridization with the 
human leptin and leptin receptor long isoform probes (see Methods and Materials Table 1). 
The results of ISH assay for leptin and leptin receptor long (LRL) isoform expression in the 
previously mentioned normal (see Results Figure 4 and 5), adenoma (see Results Figure 6 and 7), and 
hyperplastic (see Results Figure 8 and 9) samples of human parathyroid as well as normal human adipose 
tissue serving as a positive control (see Results Figure 10) are shown. The antisense (AS) probes detected 
the mRNA while the sense (S) probes did not hybridize but showed the background level of silver grains 
for the assay. Normal parathyroid sections were small enough that most of them were contained in a 25x 
image. The other diseased parathyroid samples were also photographed at 6.25x magnification. All 
images reported are from two-week exposures to nuclear track emulsion. In summary, leptin and LRL 
gene transcripts were detected in an overlapping fashion in secretory cells in all of the samples. The level 
of expression varied between the samples. Normal and hyperplastic parathyroids showed the highest 
expression levels. The adenomas showed low levels of expression that were similar in samples A, B and 
C. Leptin and LRL were co-expressed in the secretory (chief) cells of the parathyroid parenchyma in the 
normal, hyperplasia and adenoma samples. Neither of these gene transcripts was detected in adjacent 
thyroid follicular cells or in blood vessels, which indicated that the probes were specific for their target 
mRNAs. 
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Immunohistochemistry 
Double labeling IHC showed the presence and co-localization of leptin hormone and PTH in the 
chief cells of parathyroid adenoma (see Results Figure 11) and hyperplastic parathyroid tissue (see 
Results Figure 12). Leptin Receptor Long Isoform and PTH are similarly expressed in the peripheral body 
of chief cells in parathyroid adenoma (see Results Figure 13) and hyperplastic parathyroid tissue (see 
Results Figure 14). As a positive control, adipose tissue (see Results Figure 15) was stained positively for 
leptin and leptin receptor, but not PTH. 
Immunofluorescence Conventional Fluorescent Microscopy 
Immunofluorescent co-staining for leptin or leptin receptor and PTH on adenoma and 
hyperplastic parathyroid tissue sections found that both the leptin (see Results Figure 16 and 17) and 
leptin receptor protein (see Results Figure 18 and 19) were present in the peripheral body of chief cells in 
the diseased parathyroid tissue, with staining appearing homogenously throughout all regions of the 
parathyroid glands. Peri-glandular adipose tissue in all cases stained positively for leptin and leptin 
receptor but not PTH. This result was obtained for three hyperparathyroidism patients with adenomas and 
two with hyperplastic parathyroid disease. 
Immuno Electron Microscopy 
Ultra structural analyses of parathyroid tissue showed that leptin hormone localizes 
predominantly to the cytoplasmic cell body and associates with the golgi apparatus and endoplasmic 
reticulum but also localized near the nuclear membrane of the parathyroid chief cell (see Results Figure 
20) Parathyroid hormone was localized to positive structures composed of granular dense material 
surrounded by a membrane and was associated near the peripheral cell membrane and dispersed into the 
extracellular space (see Results Figure 21) Double labeling results revealed co-localization of leptin 
hormone and PTH hormone near the periphery and cell membrane of the chief cells unenclosed in dense 
granules but rather dispersed into the extracellular spaces (see Results Figure 22). This was similar for 
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both hyperplastic and adenoma parathyroid tissue. Double labeling results gave the same results when the 
size of the colloidal gold conjugates was reversed. 
Parathyroid Cell Culture 
Parathyroid cells taken from primary adenoma patient samples were successfully cultured in a 
monolayer and firmly attached to collagen-coated plates as shown in (see Results Figure 23). Under the 
culture medium described earlier, parathyroid chief cells proliferated and were recognized under light 
microscropy as predominantly chief cells (as opposed to oxyphil cells?) with moderate amounts of 
cytoplasm and large, hyperchromatic nuclei.  Parathyroid cells grew adequately and evaluated for 
function, specifically for PTH secretion in the culture medium during a 24-hour period. This was found to 
be markedly elevated above 2349 pg/mL.  
Immunofluorescence Spinning Disc Confocal Microscope 
Parathyroid monolayer cell cultures described previously were successfully cultured in a 
monolayer and firmly attached to collagen-coated plates. The cultures were analyzed by 
immunofluorescence by spinning disc confocal fluorescence microscopy to examine the localization of 
leptin and leptin receptors. Immunofluorescent staining for endogenous leptin and PTH in fixed adenoma 
and hyperplastic parathyroid cultured cells more clearly reveals that leptin was present throughout the 
cytoplasm and perinuclear region of chief cells in a punctate manner (see Results Figure 24). These 
conflated images are from 3D confocal stacks and individual sections indicate that the localization is 
within the cell. Fibroblast cells in the same culture had a different labeling pattern for leptin with a 
distinct absence of leptin from the cell cytoplasm (see Results Figure 25). 
 Immunofluorescent studies revealed colocalization of both PTH and Leptin (see Results Figure 
26). Co-localization studies were subsequently performed for both Leptin Receptor and PTH as well (see 
Results Figure 27). 
An immunofluorescence validation study revealed exogenous transferrin tagged with Alexa 488 
to be taken up successfully by live culture parathyroid cells (see Results Figure 28). Subsequently, live 
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culture parathyroid chief cells incubated in human recombinant leptin hormone tagged with alex 488 
(mention protocol in methods section—Invitrogen kit) showed similar exogenous leptin uptake into the 
cytoplasmic space most prominent at 30 minutes while fibroblast cells did not have exogenous leptin 
uptake (see Results Figure 29 and 30). Rather in the fibroblast, it appears that the exogenous leptin 
localized to the exterior of the fibroblast cell membrane. 
Parathyroid Tissue Explant Experiments and culture medium PTH analysis 
A total of 12 parathyroid adenomas and five hyperplastic tissue from patients were explanted and 
exposed to varying doses of human recombinant Leptin protein (0, 5, and 100ng/mL concentrations) and 
assayed for PTH secretion (radioimmunoassay counts per minutes) into the culture medium. 
Qualitatively, 11 of the 15 tissues (8 of 10 adenoma and three of five hyperplasia samples) explanted 
resulted in higher PTH-secretion when exposed to human recombinant leptin (see Results Figure 31A-P) 
compared to no Leptin exposure conditions clearly by the first 25 minutes; the effect continues through 
500 minutes after leptin exposure. The 100ng/mL Leptin exposure resulted in the highest PTH secretion.  
In further experimentation, parathyroid tissue incubated in AG490 (a JAK2/STAT3 small 
molecule inhibitor) in an effort to block the leptin receptor-signaling pathway and subsequently exposed 
to Leptin resulted in lower levels of PTH secretion as compared to tissues not exposed to AG490 (see 
Results Figure 31E,F,G,H,O and P). Similarly, parathyroid samples were incubated in Ly294002 prior to 
Leptin exposure in an effort to block downstream PI3K activity along the leptin receptor-signaling 
pathway, but there was no subsequent decrease in PTH secretion (see Results Figure 31C) when 
compared to non-Ly294002 incubated parathyroid tissues. 
A repeated ANOVA analysis pooling the PTH secretion values for all the parathyroid samples 
incubated in AG490 and their corresponding normal conditions, revealed that AG490 resulted in 
statistically significant inhibition of PTH secretion (see Results Table 2). The inhibition of PTH secretion 
was strongest for conditions in which parathyroid tissue was exposed to AG490 and subsequently the 
highest dose of leptin at 100ng/mL (see Results Table 3 and Results Figure 32).  
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Table 2: ANCOVA Analysis of PTH Secretion in Normal vs AG490 Inhibited 
Parathyroid Explants Exposed to No, Low, and High Leptin Conditions 
                                        
Solution for Fixed Effects 
                                           
          Standard 
 Effect       Explant Conditions          Level     Estimate       Error      DF    t Value    Pr > |t| 
 Intercept                                            947.03      465.51        8        2.03       0.0763 
 baseline                                            -0.1225     0.09535      75      -1.28      0.2028 
 condition    AG490                           -270.04     76.1144       75      -3.55      0.0007 
 condition    Normal                                    0           .          .         .             .    
 leptin          None             0           179.15      550.07          8        0.33       0.7530 
 leptin          Low                   1          -708.81      698.72          8       -1.01      0.3401 
 leptin          High                  2                0            .             .             .             .  
 time                                                 1.2841      0.5150          75        2.49      0.0149 
 time*time                                          -0.00138  0.000714      75       -1.94      0.0565 
 
 
Table 3: ANCOVA Analysis of PTH Secretion in Normal vs AG490 Inhibited Parathyroid 
Explants Exposed to High Leptin Conditions 
 
Solution for Fixed Effects 
 
Effect       Explant Conditions          Estimate       Standard Error   DF     t Value    Pr > |t|   Intercept                                 
     1107.70       584.58        4        1.89       0.1310 
baseline                                   -0.1823       0.1537      29       -1.19      0.2453   
condition    AG490                          -336.74       101.31       29       -3.32      0.0024 
       condition    Normal                              0             .                .         .            . 
time                                         1.8876       0.8481       29       2.23       0.0340   
time*time                                -0.00205     0.001177       29       -1.74      0.0926 
 
 
Type 3 Tests of Fixed Effects 
 
Effect          Num DF   Den DF     F Value     Pr > F 
baseline          1        29         1.41      0.2453 
              condition       1         29        11.05      0.0024 
time             1        29        4.95      0.0340 
time*time        1       29         3.03      0.0926 
 
 
Parathyroid Xenograft in Nude Rat model  
4 samples of parathyroid tumors, 3 adenomas and 1 hyperplastic tissue sample from patients 
undergoing parathyroidectomies, implanted submuscularly on the dorsum of Rowett nude rats as depicted 
(see Results Figure 33). 
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All four xenografts have given rise to tumors in the Rowett nude rats. When minced solid tumor 
pieces were implanted into the rats, a small tumor nodule was not palpably evident at 4-6 weeks. 
However, from the xenografted rats, blood was sampled for human and rat leptin (see Results Table 4). 
These studies revealed the presence of human leptin at 2, 4, and 8 weeks in increasing trend for adenoma 
xenografts, and decreasing trend for the hyperplasia xenografts  (see Results Figure 34). Control rats 
implanted with Alloderm or Cymmettra revealed an absence of human leptin systemically. Furthermore, 
each rat had positive rat leptin values. 
These results indicate that our animal model is reliable. For the histology of parathyroid 
adenomas arising in rats after explantation at 8 weeks from the original patient samples (see Results 
Figure 35). Parathyroid hyperplasia tissue transplanted was not grossly viable at 10 weeks for histological 
evaluation. 
Table 4: Human and Rat Leptin Serum Levels in Rowett Nude Rats Xenografted with 
Parathyroid Diseased Glands 
Sample Xenografted Human Leptin Sampled 
Human Leptin 
(ng/mL) 
Rat Leptin 
Sampled 
Rat Leptin 
(ng/mL) 
Rat 1 (Hyperplasia JA) 4.20.11 5.09.11 0.9 
  " " 5.20.11 0.87 
  " " 6.23.11 0 6.23.11 3.51 
Rat 2 (Adenoma KK) 4.19.11 5.09.11 0.38 
  " " 5.20.11 0.515 
  " " 6.23.11 0.91 6.23.11 2.75 
Rat 3 (Adenoma TD) 4.13.11 5.09.11 0.43 
  " " 5.20.11 0.595 
  " " 6.23.11 1.21 
  Rat 4 (Adenoma SM) 4.13.11 5.09.11 0.68 
  " " 5.20.11 0.89 
  " " 6.23.11 0.995 6.23.11 2.67 
Rat 5 (Alloderm) 5.03.11 5.20.11 0 6.23.11 1.42 
Rat 6 (Alloderm) 5.03.11 5.20.11 0 
  Rat 7 (Alloderm) 5.03.11 6.23.11 0 5.20.11 3.39 
Rat 8 (Cymettra) 5.03.11 6.23.11 0 6.23.11 2.75 
Rat 9 (Alloderm) 5.04.11 -- -- 6.23.11 3.81 
Rat 10 (Alloderm) 4.03.11 -- -- 5.20.11 5.86 
" " -- -- 6.23.11 4.77 
Rat 11 (Cymettra) 5.03.11 -- -- 5.20.11 1.89 
Rat 12 (Nothing) -- -- -- 5.20.11 3.51 
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Perioperative Serum Leptin Levels  
Comparing measurements between time 2 and time 3, we found that both Leptin and PTH levels 
decrease significantly after surgery in the whole patient cohort (P<0.0001) (see Results Table 5 and 
Figure 36). Specifically, Leptin decreases significantly in the adenoma (P<0.0001), median decrease in 
2.6ng/mL, and hyperplasia subgroups (p=0.0002), median decrease of 4.3ng/mL, while Leptin levels 
increased significantly in the control group (p=0.007), with median increase of 1.9 ng /ml (see Results 
Table 6).  
Table 5: Leptin and PTH Levels Collected at Pre and Post Surgery Time Points 
 
 Leptin Levels PTH Levels 
 Time 1 
1-2 months 
pre-surgery 
Time 2 
15 min - 1 
hr pre- 
surgery 
Time 3 
30 min - 1 
hr post 
surgery 
Time 4 
2 week - 1 
month post 
surgery 
Time 1 
1-2 months pre-
surgery 
Time 2 
15 min - 1 hr 
pre-surgery 
Time 3 
30 min - 1 hr 
post surgery 
Time 4 
2 week - 1 
month post 
surgery 
Overall  
20.7 
4.8 – 68.4 
43 
 
17.8  
2.0 - 117.6 
96 
 
16.2 
0.8 - 88.6 
95 
 
21.4 
2.7- 73.9 
59 
 
124.0  
44.0 – 2613 
86 
 
109.5 
50.0 – 2600 
84 
 
27.0 
11.0 – 234.0 
45 
 
42.0  
3.0 – 373.0 
45 
Median 
Range 
Sample # 
Adenoma  
20.0 
4.8 - 68.4 
39 
 
17.2 
2.2 - 117.6 
71 
 
13.9 
0.8 - 88.6 
70 
 
20.9 
3.9 - 71.9 
46 
 
115.0 
58.0 - 362 
71 
 
106.0  
50.0 - 232.0 
71 
 
27.0  
13.0 - 93.0 
71 
 
46.0  
3.0 - 213.0 
34 
Median 
Range 
Sample # 
Hyperplasia  
32.6 
26.8 - 38.4 
2 
 
21.8 
2.0 - 77.6 
13 
 
18.6 
1.2 - 63.7 
13 
 
49.1  
2.7 - 73.9 
7 
 
214.0 
44.0 - 2613.0 
13 
 
169.0  
57 - 2600 
13 
 
51.0  
11.0 - 234.0 
13 
 
17.0  
3.0 - 373.0 
11 
Median 
Range 
Sample # 
Control  
17.0 
10.3 - 23.7 
2 
 
10.8 
4.4 - 30.5 
12 
 
16.6 
3.8 - 39.7 
12 
 
22.7 
4.5 - 27.1 
6 
 
141.0 
51.0 – 231.0 
2 
 
 
- 
 
 
- 
 
 
- 
Median 
Range 
Sample # 
 
An ANCOVA model was built to further test the difference of perioperative changes in Leptin 
between control group and disease groups (adenoma and hyperplasia subgroups combined), adjusting for 
pre-surgery leptin level. A significant difference was detected between control group and disease group 
(p<.0001) and the change in the diseased was 5.7 ng /ml larger than that in controls. Similarly, PTH also 
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decreased significantly in adenoma (P<0.0001) and hyperplasia subgroups (p=0.0002). However, a 
comparison to controls was unable to be performed because the PTH measurements for control patients 
were not clinically available at time points 2, 3 and 4.  
Comparing measurements between time 1 and time 4, we found that there was a significant 
decrease in PTH measurements at time 4 considering the whole cohort (p<0.0001), and adenoma 
(p<0.0001) and hyperplasia subgroups (P=0.001) separately.  However, there was no significant 
difference in Leptin measurements between time 1 and time 4 in either the whole cohort or the different 
disease subgroups. 
Table 6: Paired Comparisons between Pre and Post Surgery Levels of Leptin and PTH 
Comparison Leptin PTH Difference* P-value‡ Difference * P-value‡ 
Time 1 vs. 4     
Overall 
Median 
Min – Max 
Sample N 
 
0.8  
-35.7 – 17.8 
34 
 
0.482 
 
95.0 
-48.0 – 2240 
45 
 
< .0001 
Adenoma 
Median 
Min – Max 
Sample N 
 
0.9  
-35.7 – 17.8 
31 
 
0.514 
 
74.0 
-48.0 – 284.0 
34 
 
< .0001 
Hyperplasia 
Median 
Min – Max 
Sample N 
 
0.1 
-3.1 – 3.3 
2 
 
- 
 
261.0 
21.0 – 2240 
11 
 
0.001 
Control 
Median 
Min – Max 
Sample N 
 
-0.3 
- 
1 
-  Not collected 
 
- 
 
Time 2 vs. 3     
Overall 
Median 
Min – Max 
Sample N 
 
2.2 
-10.6 – 29.0 
95 
 
<.0001 
 
76.5 
4.0 – 2470 
45 
 
< .0001 
Adenoma 
Median 
Min – Max 
Sample N 
 
2.6 
-6.1 – 29.0 
70 
 
<.0001 
 
72.0 
15.0 – 202.0 
71 
 
< .0001 
Hyperplasia 
Median 
Min – Max 
Sample N 
 
4.3 
0.3 – 19.8 
13 
 
0.0002 
 
142.0 
4.0 – 2470.0 
13 
 
0.0002 
Control 
Median 
Min – Max 
Sample N 
 
-1.9 
-10.6 – 0.6 
12 
 
0.007 
 
- 
 
- 
* Difference is presented as median (upper panel), minimum – maximum (middle panel) and N (lower 
panel); ‡ Wilcoxon Signed Rank test; - Not applicable due to clinical samples not collected. 
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Results Figure 37 shows that the there was no significant correlation between the absolute 
perioperative changes in Leptin and PTH in patients with an adenoma or hyperplasia.  The Pearson 
correlations and corresponding p values were 0.06 (p=0.62) for the adenoma group, 0.03 (p=0.93) for the 
hyperplasia group, and 0.09 (p=0.44) for both groups combined overall. 
However, when removing subject effects and analyzing the within-subject correlation between 
perioperative changes in Leptin and PTH level, a decrease in Leptin levels are seen to be significantly 
associated with a decrease in PTH levels (r=0.32, p=0.003) after surgery when looking at the combined 
total cohort (see Results Table 7 and Figure 38). Examining each disease subgroup separately, the within-
subject correlation was significant for the adenoma group (r=0.55, p<.0001), but was not significant for 
the hyperplasia group (r=0.42, 0.133).  
 
Table 7: Within-Subject Correlation between Leptin and PTH Pre and Post Surgery 
 
Time Point 2 vs. 3 
 
r 
 
R2 
 
p-value 
Overall 0.32 0.10 0.003 
Adenoma 0.55 0.30 <.0001 
Hyperplasia 0.42 0.18 0.133 
 
Bivariate Analyses on Baseline Leptin Level 
Note: The measurement of Leptin at time point 2 will be considered as baseline level when 
analyzing the association of different clinical characteristics to baseline hormone level because 1) there 
were only 43 among 96 subjects with available leptin measurement at time point 1; 2) For these 43 
subjects, there was no statistical difference between leptin level at time point 1 and at time point 2 
(p=0.432, Wilcoxon Rank Sum test); 3) subjects were restricted in some condition such as diet at time 
point 2 for surgery so that the effect of unknown factors on leptin levels may be minimized. 
Table 8 reveals bivariate analysis of baseline leptin hormone levels with different clinical 
characteristics. Those variables found to be associated with baseline leptin levels include: parathyroid 
disease subtype, gender, body mass index (BMI), number of parathyroids removed during surgery, and 
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Vitamin D 25-OH levels. When controlling for all variables in a multivariate analysis (Table 9), only 
parathyroid disease subtype, gender, and BMI remained significantly associated with baseline leptin 
hormone values. 
Table 8: Bivariate Analysis on Baseline Leptin Hormone Levels Prior to Surgery 
Characteristics   Leptin (pre-surgery) 
 Estimate (SE) p-value 
Subtype   0.067 
Adenoma  7.18 (5.93) 0.226 
Hyperplasia  17.86 (7.61) 0.019 
Control  0  
Gender (Female vs. Male)  13.41 (4.52) 0.004 
Fosamax / Sensipar Use (Y vs. N)  7.09 (5.55) 0.204 
BMD   0.662 
Normal  0  
Osteopenia  -4.46 (5.12) 0.384 
Osteoporosis  -0.70 (5.17) 0.893 
BMI   <.0001 
Obesity  27.12 (4.29) <.0001 
Overweight  11.60 (4.39) 0.010 
Underweight or Normal  0  
# of parathyroid glands removed  4.22 (1.90) 0.029 
Leptin 1  1.06 (0.09) <.0001 
PTH 1   -0.0004 (0.006) 0.946 
PTH 2  -0.002 (0.007) 0.816 
Age  0.24 (0.17) 0.155 
SBP  -0.02 (0.12) 0.872 
DBP  -0.04 (0.19) 0.829 
Calcium at diagnosis  3.99 (2.46) 0.108 
Vitamin D 25-OH  -0.46 (0.19) 0.019 
Cr  0.05 (0.75) 0.953 
TSH  -0.07 (0.10) 0.485 
Total wt parathyroid removed  0.002 (0.001) 0.114 
 
 
Table 9: Multivariate Analysis on Baseline Leptin Level 
Effects Leptin (pre-surgery) (n=96) Estimate (SE) p-value 
Subtype  0.0001 
Adenoma 10.15 (4.17) <.015 
Hyperplasia 19.6 ((5.33) 0.0002 
Control 0  
Gender  
(♀ vs Male) 
8.13 (1.60) <.0001 
BMI 1.59 (0.18) <.0001 
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Table 10 depicts the bivariate analysis of baseline parathyroid hormone (time point 1 = baseline 
months out from surgery while time point 2 = preoperative baseline morning of surgery) levels with 
different clinical characteristics. Those variables found to be associated with baseline parathyroid levels 
include: parathyroid disease subtype, use of Fosamax and sensipar baseline leptin levels at time point 1, 
age, calcium at time of diagnosis, vitamin D 25-OH, Creatinine, and eventual number and weight of 
parathyroid glands removed postoperatively. When controlling for all variables in a multivariate analysis 
(Table 11), only vitamin D 25-OH, Creatinine, and eventual number and weight of parathyroid glands 
removed postoperatively remained significantly associated with baseline PTH values. 
Table 10: Bivariate Analyses on PTH Level at Time Point 1 and 2 
Dependent Variable   PTH time 1 PTH time 2 
Predictor n Estimate (SE) p-value N Estimate (SE) p-value 
Subtype* 84  <.0001 84  <.0001 
Adenoma  -486.58 (94.90)   -401.58 (85.25)  
Hyperplasia  0   0  
Gender (Female vs. Male) 86 -77.87 (87.98) 0.379 84 -52.60 (80.82) 0.517 
Fosamax Sensipar US (Y vs. N) 83 415.05 (62.93) <.0001 81 339.34 (85.42) 0.0002 
BMD 84  0.341 82  0.358 
Osteopenic  21.83 (94.46) 0.237  50.69 (85.44) 0.553 
Osteoporosis  -110.40 (93.32) 0.813  -75.98 (84.60) 0.369 
Normal  0   0  
   0.146   0.189 
Osteoporosis  -121.12 (82.54)   99.94 (75.42)  
BMI 85  0.946 84  0.871 
Obesity  -28.10 (163.02)   -34.8 (93.15) 0.710 
Overweight  -1.73 (102.41)   6.06 (92.58) 0.948 
Underweight or Normal  0   0  
Spect Sestamibi Scan (Y vs. N) 76 17.43 (33.42) 0.604 76 5.93 (23.05) 0.798 
Leptin 1 42 1.15 (0.46) 0.018 41 0.96 (0.31) 0.004 
Leptin 2 86 -0.13 (1.89) 0.946 84 -0.40 (1.72) 0.816 
PTH 1  - - - 84 0.87 (0.02) <.0001 
PTH 2 - - - - - - 
Age 84 -7.64 (3.15) 0.017 84 -5.10 (2.90) 0.082 
BMI 86  2.36 (5.30) 0.657 84 -2.83 (4.76) 0.554 
SBP 86 -0.94 (2.24) 0.675 84 -1.15 (2.03) 0.573 
DBP 86 -1.74 (3.77) 0.646 84 -2.65 (3.38) 0.435 
Calcium at diagnosis 86 -180.98 (51.50) 0.0007 84 -174.15 (49.24) 0.0007 
Vitamin D 25-OH 73 -2.97 (1.01) 0.004 73 -1.72 (0.70) 0.016 
Cr  81 93.80 (9.66) < .0001 79 79.87 (9.18) <.0001 
TSH 66 -0.79 (1.69) 0.641 64 -0.23 (1.70) 0.890 
# of parathyroid removed 86 161.99 (34.95) <.0001 84 140.91 (32.66) < .0001 
Weight of parathyroid removed  83 0.17 (0.06)   0.006 83 0.15  (0.05)  0.006 
* Control group had no PTH measurements across all time points.  
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 Table 11: Multivariate Analysis on PTH Level at Time Point 1 or 2 
Effects PTH at time 1 (n=67) PTH  at time 2 (n=67) 
Estimate (SE) p-value Estimate (SE) p-value 
Subtype  0.019  0.058 
Adenoma -179.82 (74.62)  -114.79 (59.48)  
Hyperplasia 0  0  
Number of parathyroid 
removed 
-66.72 (28.32) 0.022 -34.93 (22.57) 0.127 
Weight of parathyroid 
removed 
0.06 (0.02) 0.0003 0.05 (0.01) 0.0003 
Vitamin D 25-OH -2.11 (0.74) 0.006 -1.09 (0.59) 0.071 
Cr 49.58 (7.78) <.0001 24.12 (6.20) 0.0003 
 
 
Table 12 reveals bivariate analysis of changes in perioperative leptin hormone and  parathyroid 
hormone levels, respectively, between time point 2 and 3 again with different clinical characteristics. 
Those variables found to be associated with changes in leptin levels include: parathyroid disease subtype, 
gender, bone mineral density, BMI, baseline leptin levels at time point 1, baseline leptin levels at time 
point 2, age, calcium at time of diagnosis, and eventual number of parathyroid glands removed 
postoperatively. When controlling for all variables in a multivariate analysis (Table 13), only parathyroid 
disease subtype, starting leptin levels at time point 2, age, BMI, and calcium at diagosis remained 
significantly associated with changes in leptin hormone values from time point 2 to 3. 
Alternatively, bivariate analysis found the following variables found to be associated with 
changes in PTH levels perioperatively: parathyroid disease subtype, use of Fosamax/sensipar baseline 
leptin levels at time point 1 only, baseline PTH level at time point 1, PTH levels at time point 2, age, 
calcium, Vitamin D 25-OH, and creatinine at time of diagnosis, and eventual number and weight of 
parathyroid glands removed postoperatively. When controlling for all variables in a multivariate analysis 
(Table 13), only PTH levels at time point 2, and number of parathyroid glands removed operatively 
remained significantly associated with changes in PTH values from time point 2 to 3.  
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Table 12: Bivariate Analyses on Change in Leptin & PTH Pre & Post surgery 
Dependent Variable Leptin Change  PTH Change   
Predictor  Estimate (SE) p-value  Estimate (SE)  p-value 
Subtype   <.0001    
Adenoma  7.24 (1.70) <.0001  -360.0(81.4) <.0001 
Hyperplasia  9.74 (2.18) <.0001  0  
Control  0   -  
Gender (Female vs. Male)  3.11 (1.43) 0.032  -42.5 (75.50) 0.575 
BMD   0.137   0.380 
Osteopenic  0.08 (1.53) 0.956  49.70 (79.80) 0.534 
Osteoporosis  2.81 (1.53) 0.066  -65.66 (79.04) 0.406 
Normal  0   0  
BMI   0.007   0.804 
Obesity  4.69 (1.54) 0.003  - 29.5 (86.9) 0.735 
Overweight  4.16 (1.58) 0.010  20.81 (86.34) 0.810 
Underweight or Normal  0   0  
Leptin 1  0.23 (0.05) < .0001  0.88 (0.30) 0.006 
Leptin 2  0.23 (0.02) < .0001  -0.32 (1.60) 0.840 
PTH 1   0.001 (0.002) 0.537  0.80 (0.02) <.0001 
PTH 2  0.001 (0.002) 0.482  0.93 (0.01) <.0001 
Age  0.16 (0.05) 0.001  -4.38 (2.71) 0.110 
BMI  0.18 (0.08) 0.024  -2.43 (4.45) 0.587 
SBP  -0.02 (0.04) 0.593  -1.24 (1.90) 0.515 
DBP  -0.01 (0.06) 0.852  -2.72 (3.16) 0.392 
Calcium at diagnosis  1.66 (0.75) 0.029  -149.23 (46.51) 0.002 
Vitamin D 25-OH  -0.07 (0.06) 0.228  -1.70 (0.64) 0.010 
Cr  0.22 (0.23) 0.332  73.37 (8.70) <.0001 
TSH  -0.02 (0.03) 0.568  -0.21 (1.63) 0.900 
# of parathyroid removed  1.84 (0.57) 0.002  125.43(30.80) 0.0001 
Parathyroid weight removed 
 
 0.0009 (0.001)        0.396      0.14 (0.05) 0.0057 
 
Table 13: Multivariate analyses on change in Leptin/PTH level pre and post surgery 
 Leptin Change  
n=93 
PTH Change  
n=84 
Predictor Estimate (SE) p-value Estimate (SE) p-value 
 
Subtype 
  
0.0001 
  
Adenoma 6.11 (1.33) <.0001   
Hyperplasia 5.86 (1.53) 0.0001   
Control 0    
Leptin pre-surgery 0.26 (0.02) < .0001   
Age 0.09 (0.03) 0.008   
BMI -0.19 (0.06) 0.002   
Calcium at diagnosis -1.06 (0.54) 0.054   
PTH pre-surgery   0.94 (0.01) < .0001 
# of parathyroid removed   -6.92 (3.10) 0.028 
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Two other correlations were found between patient BMI and the total weight or number of 
parathyroid removed from each patient (Results Table 14 and Figure 39) as well as number of glands and 
total weight of glands removed (Results Table 15). 
                                        
Table 14: Pearson Correlation of BMI and total weight or number of parathyroid removed 
 
Variable    N  Mean         Std Dev  Median            Minimum         Maximum 
Total Weight Removed (mg) 84  803.45   1609  373.50  35.00  14190 
# of glands    96  1.31   1.03          1.00   0                4.00 
BMI (lbs/in^2)    96  29.67   7.78   28.24   16.48  57.72 
 
 BMI Total Weight Removed (mg) # of glands 
Pearson Correlation Coefficients  0.35401 0.01539 
Prob > |r| under H0: Rho=0  0.0010 0.8817 
Number of Observations  84 96 
  
 
                                             
Table 15: Pearson correlation coefficients= -0.0008, p=0.99 for Number of gland removed 
and weight of gland removed 
 
                         Analysis Variable: Total Weight Removed (mg) 
 
                
 # glands     N         Mean        Std Dev              Median         Minimum         Maximum 
 
 
         1         63    856.17         1826.47       348.00          35.00         14190.00 
 
         2         8    222.38      152.41            152.50       84.00       485.00 
 
         3         5     689.80       708.91     440.00      127.00        1921.00 
 
         4         8    1040.38      603.18     874.50     394.00      1998.00 
 
 
 
Adipose Tissue Explant Experiments and Culture Medium Leptin Hormone Analysis 
Parathyroid hormone 1-84 amino acids stimulated leptin hormone release into culture media of 
adipose tissue explants in detectable quantities compared to no effect of isoproterenol and Parathyroid 
hormone 1-34 amino acids on the release of leptin hormone (see Results Figure 40).  
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Summary of Findings 
 
• Leptin is expressed in parathyroid glands at the mRNA and protein level 
o Parathyroid hyperplasia expresses leptin at greater quantities than adenoma 
o Verified by in-situ hybridization, immunohistochemistry, immunofluorescence, 
immuno electron microscopy 
• Leptin does not colocalize with PTH secretory granules intracellularly in 
parathyroid secretory chief cells, but does colocalize near the cell membrane 
o Verified by in-situ hybridization, immunohistochemistry, immunofluorescence, 
immune-electron microscopy 
• Leptin influences PTH secretion in a dose dependent manner in explanted 
parathyroid tissue 
o AG490 inhibition appears to abrogate such effects, especially in the presence of 
high leptin conditions (100 ng/mL) 
o LY294002 inhibition was not found to have abrogating effects on PTH secretion 
in the presence of leptin exposure 
• Leptin is secreted into systemic circulation 
o Xenografts of parathyroid tissue into nude rats subsequently revealed positive 
levels of human leptin hormone 
o Xenografts of parathyroid tissue into Ob/Ob mice subsequently revealed 
excessive weight loss and leptin induced symptoms 
• Serum Leptin levels decrease perioperatively after diseased parathyroid glands are 
surgically removed 
o Median decrease in adenoma patients’ leptin levels of 2.6 ng/mL 
o Median decrease in hyperplasia patients’ leptin levels of 4.3 ng/mL 
o Median increase in control hemithyroid patients’ leptin levels of 1.9 ng/mL 
• Parathyroid Hormone 1-84 amino acid stimulates leptin release from adipose tissue 
explants 
o No significant leptin hormone release was found with exposure to parathyroid 
hormone 1-34 amino acid length and isoproterenol 
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Figures of Results (1-40) 
 
Figure 1 
 
Validation of Normal Parathyroid mRNA Content 
    
 
    
A Darkfield image of normal parathyroid tissue after ISH with the antisense probe for vWF and emulsion 
autoradiography. Labeling reveals a ubiquitous pattern of vWF mRNA distribution, seen as bright 
labeling on dark background. 
B Control (vWF sense) hybridization of a section comparable to that shown in (A). 
C Darkfield image of normal parathyroid tissue after ISH with the antisense probe for PTH and emulsion 
autoradiography. Labeling reveals a ubiquitous pattern of PTH mRNA distribution, seen as bright 
labeling on dark background. 
D Control (PTH sense) hybridization of a section comparable to that shown in (C). 
 
  
A B 
C D 
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Figure 2 Validation of Parathyroid Adenoma mRNA Content 
    
 
    
A Darkfield image of parathyroid adenoma (Sample A) tissue after ISH with the antisense 
probe for vWF and emulsion autoradiography. Labeling reveals a ubiquitous pattern of vWF 
mRNA distribution, seen as bright labeling on dark background. 
B Control (vWF sense) hybridization of a section comparable to that shown in (A). 
C Darkfield image of parathyroid adenoma (Sample A) tissue after ISH with the antisense probe for PTH 
and emulsion autoradiography. Labeling reveals a ubiquitous pattern of PTH mRNA distribution, seen as 
bright labeling on dark background. 
D Control (PTH sense) hybridization of a section comparable to that shown in (C). 
 
  
A B 
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Figure 3 Validation of Hyperplastic Parathyroid mRNA content 
    
 
    
A Darkfield image of hyperplastic parathyroid tissue after ISH with the antisense probe for vWF 
and emulsion autoradiography. Labeling reveals a ubiquitous pattern of vWF mRNA 
distribution, seen as bright labeling on dark background. 
B Control (vWF sense) hybridization of a section comparable to that shown in (A). 
C Darkfield image of hyperplastic parathyroid tissue after ISH with the antisense probe for PTH and 
emulsion autoradiography. Labeling reveals a ubiquitous pattern of PTH mRNA distribution, seen as 
bright labeling on dark background. 
D Control (PTH sense) hybridization of a section comparable to that shown in (C). 
 
  
A B 
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Figure 4 Leptin mRNA Expression in Normal Parathyroid 
 The background level of silver grains for the leptin probe was higher than that for the LRL probe, but 
was below the level of silver grains for the leptin antisense probe. 
A Detection of leptin mRNA expression in normal parathyroid seen as bright labeling under darkfield 
illumination. Leptin mRNA expression was detected throughout the sample. 
B Control (sense) hybridization in an adjacent section comparable to (A). This probe showed non-
specific adhesion to the glass as well as the tissue sections as indicated by the silver grains on either 
side of the section. 
C Phase contrast image of the section shown in (A). 
 
  
A B 
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Figure 5 Leptin Receptor Long Isoform mRNA Expression in Normal Parathyroid 
A Detection of LRL mRNA expression in normal parathyroid seen as bright labeling under darkfield 
illumination. LRL mRNA expression was detected in all regions of the normal parathyroid. 
B Control (sense) hybridization in an adjacent section comparable to (A). The background level of 
silver grains for this probe was low. 
C Phase contrast image of the section shown in (A). Portions of this tissue were torn during sample 
preparation and sectioning. 
  
A B 
C 
	  	   46	  
 
  
 
  
 
 
 
Figure 6 Leptin mRNA Expression in Parathyroid Adenoma  
A Detection of leptin mRNA expression in parathyroid adenoma Sample A seen as bright labeling under 
darkfield illumination. Leptin mRNA expression appeared slightly higher than LRL mRNA 
expression in this sample, but both genes were expressed at a lower level than that detected in normal 
and hyperplastic samples. 
B Control (sense) hybridization in an adjacent section comparable to (A). 
C Higher magnification of the same section shown in (A) shown under darkfield illumination. Leptin 
mRNAs were detected in the secretory cells of the adenoma but not in the endothelium or smooth 
muscle layers of a blood vessel (bv). 
D Higher magnification of the same section shown in (B) shown under darkfield illumination. 
E Phase contrast image of the section shown in (C) showing the blood vessel (bv). 
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Figure 7 Leptin Receptor Long Isoform mRNA Expression in Parathyroid Adenoma 
A Detection of LRL mRNA expression in parathyroid adenoma Sample A seen as bright labeling under 
darkfield illumination. LRL mRNAs were detected at a low level in this sample. 
B Control (sense) hybridization in an adjacent section comparable to (A). 
C Higher magnification of the same section shown in (A) shown under darkfield illumination. 
D Higher magnification of the same section shown in (B) shown under darkfield illumination. LRL gene 
expression was above background in this tissue sample. 
E Phase contrast image of the section shown in (C). 
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D C 
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Figure 8 Leptin mRNA Expression in Hyperplastic Parathyroid 
A Detection of leptin mRNA expression in hyperplastic parathyroid seen as bright labeling under 
darkfield illumination. Leptin mRNA expression was detected in the parathyroid (p) components of 
this sample but not in the follicular cells of the thyroid (t) components. 
B Control (sense) hybridization in an adjacent section comparable to (A). Although the background is 
high for this probe the level of silver grains is still significantly lower than the antisense result. 
C Higher magnification of the same section shown in (A) shown under darkfield illumination. Leptin 
mRNAs were detected in parathyroid cells but not in thyroid (t) follicles. Leptin mRNAs overlapped 
with LRL gene transcripts. 
D Higher magnification of the same section shown in (B) shown under darkfield illumination. 
E Phase contrast image of the section shown in (C). 
  
A B 
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Figure 9 Leptin Receptor Long Isoform mRNA Expression in Hyperplastic Parathyroid 
A Detection of LRL mRNA in a hyperplastic parathyroid sample featuring parathyroid cells (arrows) 
and thyroid follicles seen as bright labeling under darkfield illumination. LRL mRNA expression 
was detected in the parathyroid components of this sample but not in the follicular cells of the 
thyroid components. 
B Control (sense) hybridization in an adjacent section comparable to (A). 
C Higher magnification of the same section shown in (A) shown under darkfield illumination. This 
image demonstrates that probe hybridization was specific to the parathyroid cells. 
D Higher magnification of the same section shown in (B) shown under darkfield illumination. Folds in 
the tissue sections appear as lighter areas under darkfield illumination. 
E Phase contrast image of the section shown in (C) showing mostly parathyroid with a small number 
of thyroid (t) follicles in the top left and bottom right corners.  
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Figure 10 Leptin mRNA Expression in Unilocular Normal Adipose Tissue (Probe Validation 
using positive control) 
A Detection of leptin mRNA expression in unilocular fat cells seen as bright labeling under darkfield 
illumination. Silver grains were localized over adipocyte nuclei and cytoplasm. 
B Control (sense) hybridization in an adjacent section comparable to (A). The background for this probe 
was low on this tissue. 
C Phase contrast image of the section shown in (A) 
 
 
Figure 11: Immunohistochemical co-localization of Leptin and PTH (Adenoma) 	  
    
Immunohistochemical co-localization of Leptin (Ob A-20, brown) and PTH (BGN/1F8, red) epitopes in a 
parathyroid adenoma at 60x magnification under light microscopy. Note overlapping and non-overlapping 
labeled areas in the perinuclear space of chief cell bodies. 
A B 
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Figure 12: Immunohistochemical co-localization of Leptin Receptor and PTH (Adenoma) 
 
      
 
 
      
 
 
 
Immunohistochemical co-localization of Leptin Receptor (Ob-R H-300, brown) and PTH (BGN/1F8, red) 
epitopes in a parathyroid adenoma at 60x magnification under light microscopy. Again, note overlapping 
and non-overlapping labeled areas in chief cell bodies. 
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Figure 13: Immunohistochemical co-localization of Leptin and PTH (Hyperplasia) 
 
      
 
      
Immunohistochemical co-localization of Leptin (Ob A-20, brown) and PTH (BGN/1F8, red) epitopes in 
hyperplastic parathyroid tissue at 60x magnification under light microscopy. Note overlapping and non-
overlapping labeled areas in the perinuclear space of chief cell bodies. 
 
Figure 14: Immunohistochemical co-localization of Leptin Receptor and PTH 
(Hyperplasia)  
  
      
Immunohistochemical co-localization of Leptin Receptor (Ob-R H-300, brown) and PTH (BGN/1F8, red) 
epitopes in hyperplastic parathyroid tissue at 60x magnification under light microscopy. Again, note 
overlapping and non-overlapping labeled areas in chief cell bodies. 
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Figure 15: Immunohistochemical staining of Leptin & Leptin Receptor in adipose tissue 
      
Immunohistochemical dual staining of Leptin (Ob A-20, brown) (left – 40x magnification under light 
microscopy) or Leptin Receptor long isoform (Ob-R H-300, brown) (right – 60x magnification) and PTH 
(BGN/1F8, red) in positive control adipose tissue. Note absence of red staining.  
 
 
Figure 16: Immunofluorescence co-localization of Leptin and PTH (Adenoma)  
     
 
     
 
     
Immunofluorescence co-localization of Leptin (Ob A-20, red) and PTH (BGN/1F8, green) epitopes in a 
parathyroid adenoma at 4x (top row), 20x (middle row), and 60x (bottom row) magnification under 
fluorescent microscopy separately and when overlapped (last image on next page) [nucleus is stained 
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with DAPI (blue)]. Note dual labeling of the perinuclear space of chief cell bodies. In the 4x view, note 
staining of periglandular adipose tissue stained for Leptin but not for PTH (arrows). 
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Figure 17: Immunofluorescence co-localization of Leptin Receptor and PTH (Adenoma)  
     
 
     
         
     
 
     
Immunofluorescence co-localization of Leptin Receptor (Ob H-300, red) and PTH (BGN/1F8, green) 
epitopes in a parathyroid adenoma at 4x (top row), 20x (middle row), and 40x (bottom row) 
magnification under fluorescent microscopy and when overlapped (last image on next page) [nucleus is 
stained with DAPI (blue)]. Note dual labeling of the perinuclear space of chief cell bodies. In the 4x view, 
note staining of periglandular adipose tissue stained for Leptin receptor but not for PTH (arrows). 
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Figure 18: Immunofluorescence co-localization of Leptin and PTH (Hyperplasia) 
     
 
     
 
     
Immunofluorescence co-localization of Leptin (Ob A-20, red) and PTH (BGN/1F8, green) epitopes in 
hyperplastic parathyroid tissue at 4x (top row), 20x (middle row), and 60x (bottom row) magnification 
under fluorescent microscopy separately and when overlapped (last image on next page) [nucleus is 
stained with DAPI (blue)]. Note dual labeling of the perinuclear space of chief cell bodies. In the 4x view, 
note staining of periglandular adipose tissue stained for Leptin but not for PTH (arrows). 
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Figure 19: Immunofluorescence co-localization of Leptin Receptor and PTH (Hyperplasia)  
      
 
     
         
     
 
     
Immunofluorescence co-localization of Leptin Receptor (Ob H-300, red) and PTH (BGN/1F8, green) 
epitopes in hyperplastic parathyroid tissue at 4x (top row), 20x (middle row), and 40x (bottom row) 
magnification under fluorescent microscopy (last image on next page) [nucleus is stained with DAPI 
(blue)]. Note dual labeling of the perinuclear space of chief cell bodies. In the 4x view, note staining of 
periglandular adipose tissue stained for Leptin receptor but not for PTH (arrows). 
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Figure 20: ImmunoEM showing single labeling of Leptin (Adenoma)  
  
 
  
   
 
ImmunoEM showing single labeling of leptin (Ob A-20, 10 nm gold particles) epitopes in an adenoma 
tissue sample. A parathyroid chief cell shown with leptin staining throughout a golgi body and 
endoplasmic reticulum system with mitochondria seen in the periphery (Upper Left, Upper Right, Lower 
Left photo, bar = 1 um and 500 nm, respectively). Photo on the Lower Right shows leptin localized to a 
perinuclear location nearly adjacent to nuclear membrane, bar = 500 nm. 
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Figure 21: ImmunoEM showing single labeling of PTH (Adenoma)  
 
 
 
 
 
ImmunoEM showing single labeling of PTH (BGN/1F8, 10 nm gold particles) epitopes in an adenoma 
tissue sample. A parathyroid chief cell reveals PTH clustered inside of electron dense granules, with 
mitochondria seen in the periphery (Top and Middle photo, bar = 500 nm). Photo on the Bottom shows 
PTH localized to electron dense granules near peripheral cell membrane but also freely localizing to 
extracellular location. Cytoplasmic foot extensions near cell periphery seen, bar = 500 nm. 
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Figure 22: ImmunoEM showing double labeling of Leptin and PTH (Adenoma)
  
  
 
ImmunoEM showing double labeling of Leptin (Ob A-20, 10 nm gold particles) and PTH (BGN/1F8, 5 nm 
gold particles) near the cytoplasmic extensions/foot processes of the chief parathyroid cell (Upper Left 
and Upper Right photo, bar = 1 µm) as well as in a electron dense granule. Similarly shown at higher 
magnification (Middle Left photo, bar = 500 nm). Leptin and PTH are shown co-localizing near a blood 
vessel (Middle Right, bar = 500 nm) and in the extracellular space (Bottom, bar = 500 nm). 
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Figure 23: Parathyroid cell culture in monolayer  
     
 
    
 
      
Parathyroid cell culture in monolayer revealing firmly attached clusters of parathyroid chief cells with 
large, hyperchromatic nuclei and moderate amounts of cytoplasm at 10x (Upper Left), 20x (Upper Right, 
Middle Left), 40x (Middle Right), 60x (Bottom Left, Bottom Right). 
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Figure 24: Abundance of Cytoplasmic Immunofluorescent Labeling of Leptin  
 
    
 
    
Phase-contrast images of cultured parathyroid cells in monolayer; firmly attached clusters of parathyroid 
chief cells with large, hyperchromatic nuclei and moderate amounts of cytoplasm are seen on the left at 
high power magnification. The Upper and Middle Right images reveal an abundance of cytoplasmic 
immunofluorescent labeling of leptin probed with primary antibody Ob A-20 and secondary antibody 
tagged with GFP (green) in fixed cultured parathyroid cells. The nucleus has been Hox stained with DAPI 
(blue) while actin has been stained with anti-phalloidin tagged with RFP.  
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The two Right images on this page show negative controls of cultured parathyroid cells incubated with 
the secondary antibody tagged with GFP only without primary leptin antibody Ob A-20. 
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Figure 25: A Paucity of Cytoplasmic Immunofluorescent Labeling of Leptin 
 
    
 
Phase-contrast image of a fibroblast cell growing amongst the cultured parathyroid cells seen on the left 
at high power magnification. The right image reveals a paucity of cytoplasmic immunofluorescent 
labeling of leptin probed with primary antibody Ob A-20 and secondary antibody tagged with GFP (green) 
in the fibroblast cell. There is some speckling of green in the nucleus. The nucleus has been Hox stained 
with DAPI (blue) while actin has been stained with anti-phalloidin tagged with RFP. 
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Figure 26: Co-localization immunofluorescent labeling of PTH and Leptin  
 
 
    
  
 
   
 
Phase-contrast image of cultured parathyroid chief cells seen on the left. The right images reveals co-
localization immunofluorescent labeling of PTH probed with primary antibody and secondary antibody 
tagged with GFP (green) in the fibroblast cell and leptin probed with primary Ob A-20 and secondary 
antibody tagged with RFP. The nucleus has been Hox stained with DAPI (blue) while actin has been 
stained with anti-phalloidin tagged with Cy5.   
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Figure 27: Co-localization immunofluorescent labeling of Leptin Receptor and Leptin    
 
   
 
 
    
 
Phase-contrast image of a cultured parathyroid chief cell seen on the left. The right image at reveals co-
localization immunofluorescent labeling of Leptin Receptor probed with primary antibody Ob-R H-300 and 
secondary antibody tagged with GFP (green) in the fibroblast cell and leptin probed with primary Ob A-20 
and secondary antibody tagged with RFP. The nucleus has been Hox stained with DAPI (blue) while actin 
has been stained with anti-phalloidin tagged with Cy5. 
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Figure 28: Transferrin Uptake in Live Cultured Parathyroid Cells  
   
 
 
   
 
Transferrin tagged with Alexa 488 (green) uptake in live cultured parathyroid cells including hox-stain of 
nucleus with DAPI under phase contrast (Left) and immunofluorescence (Right) microscopy. Note, red 
blood cells do not stain for nucleus or transferrin uptake. 
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Figure 29: Recombinant Human Leptin Uptake in Live Cultured Parathyroid Chief Cells  
 
   
 
 
   
Recombinant human leptin tagged with Alexa 488 (green) uptake in live cultured parathyroid chief cells 
under phase contrast (Left images) and immunofluorescence (Right images) microscopy. Note, 
fibroblast cells do not stain for leptin uptake, rather green signaling localizes to the exterior cell 
membrane.  
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Figure 30: Recombinant Human Leptin Uptake in Live Cultured Parathyroid Chief Cells 
Video Snapshot  
 
 
 
Recombinant human leptin tagged with Alexa 488 (green) uptake in live cultured parathyroid chief cells 
under immunofluorescence (Right) microscopy snapshot of videoimaging   
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Figure 31: Parathyroid Explant Experiments 
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Fig 31M: LH067 HYPERPLASIA 
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Fig 31N: LH038 HYPERPLASIA 
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Fig 31O: LH120* HYPERPLASIA 
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Fig 31P: LH120* HYPERPLASIA 
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Figure 32: Pooled PTH Secretions of Parathyroid Samples Incubated in Normal vs. AG490 
Conditions Prior to High Leptin (100ng/mL) Exposure 
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Figure 33: Rowett Nude Rats Xenografted with Parathyroid Tissue from Patient Samples 
             
 
Rowett Nude Rats Xenografted with Parathyroid Tissue from Patient Samples Perioperatively (Left) and 
after 10 weeks (Center and Right) 
 
Figure 34: Human Leptin Serum Levels in Rowett Nude Rats Xenografted with 
Parathyroid Diseased Glands vs Control over Time 
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Figure 35: Histology of Parathyroid Tumors after Transplantation  
 
   
 
   
 
   
 
   
Histology of parathyroid tumors 10 weeks after transplantation in Rowett nude rat at 10X (Top Left and 
Right), 40X (Middle Left and Right), 60X (Bottom Left and Right). Another set at the very bottom depicts 
histology from a different parathyroid tumor at 10X (Left) and 40X (Right). 
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Figure 36: Leptin and PTH Levels Collected at Pre and Post Surgery Time Points 
 
 
 
 
2D-dot plot where lines indicate median values.  
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Figure 37: Correlation of the Absolute Change in Pre and Post Surgery Leptin and PTH 
 
 
 
 
Figure 38: Within-Subject Correlation between Pre & Post Surgery Leptin and PTH Levels 
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Figure 39: Pearson Correlation Scatter Plot of BMI vs total weight or # of glands removed 
 
 
Figure 40: Adipose Tissue Explant Exposure to Parathyroid Hormone 1-84 Amino Acids 
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DISCUSSION 	  
In our study, the biochemical evaluations at the whole organ explant to the cultured cellular level 
indicate for the first time that leptin hormone and leptin receptors are expressed in human parathyroid 
tissue in the setting of hyperparathyroid disease. Exhaustive investigations since 1994 revealed the 
presence of leptin and leptin receptor production in various tissues of the body but no study has ever 
evaluated human parathyroid glands (8, 9, 44, 45). We have substantiated the presence of leptin and leptin 
receptor mRNA and protein in parathyroid glands by ISH, IF, IHC, and EM to elucidate a foundation and 
potential mechanisms that link high leptin hormone levels to the hyperparathyroid disease state. Previous 
basic science reports have found associations between leptin hormone administration and its effect on 
circulating levels of vitamin D and PTH—these authors have gone as far to say that leptin causes an 
increase in PTH secretion but without any mention of the mechanism (82-84, 114). Leptin receptor 
presence in the renal glands were implicated in a mechanism that directly reduces vitamin D production 
and systemic levels which indirectly influenced a rise in parathyroid hormone levels (83). Other clinical 
reports corroborate the positive association between patient leptin and PTH values but were also unable to 
provide clues to a potential mechanism for that link (32, 35, 85, 87). We were only able to find a 
biochemical evaluation by Torday et al that described a scientific link between leptin production by lung 
fibroblast and the modulation of PTH-rp, but not PTH (115).  
 Our study’s experiments, specifically the electron microscopy and xenograft animal models, 
reveal that leptin is produced by the parathyroid gland and released into the extracellular space and 
circulation where it is detectable. The electron microscopy data localizes leptin to the endoplasmic 
reticulum and golgi body apparatus, which are intricately involved in endogenous secretory protein 
synthesis. The leptin hormone is not seen to colocalize in the dense granules containing PTH, but it is 
found near the cellular membrane as well as in the extracellular space as a mixture with PTH. 
Furthermore, our animal studies have shown that transplanted human diseased parathyroid adenoma 
tissues survive at least up to 8 weeks. During this time there is a detectable increase in human leptin levels 
	  	   84	  
in the animal’s serum from which the transplanted parathyroid gland is the only possible source. The 
increasing leptin levels observed may coincide with an increasing vascularity of the transplanted human 
parathyroid glands and or continued neoplastic growth. Hyperplastic tissue resulted initially in the highest 
circulating human leptin levels, but this dropped off most likely as a result of poor xenograft take. 
Furthermore, the in-situ hybridization results further confirm that leptin mRNA transcription is greater in 
hyperplastic versus adenomatous parathyroid. A similar trend exists for circulating PTH levels. 
Parathyroid gland production of leptin implicates that the observed clinical association between leptin and 
PTH levels could be a direct consequence of hyper production and secretion of both hormones by 
parathyroid glands undergoing a neoplastic or hyperplastic process. In a separate article of a prospective 
clinical study, we explore this relationship by evaluating perioperative changes in high leptin and PTH 
levels in patients receiving parathyroidectomy treatment. 
The presence of leptin receptor, specifically the long isoform, is important for leptin hormone 
influence on intracellular signaling. The short isoform of the leptin receptor has been functionally 
implicated in leptin hormone metabolism rather than facilitating leptin hormone function. As the ISH, 
IHC, and IF data show, the long isoform of the leptin receptor is present in the parathyroid glands and 
absent from surrounding thyroid tissue as well as endothelial vessels, which are known display the short 
leptin receptor isoform (41, 42, 45). With the long isoform present, functional explant experiments in 
which parathyroid tissue are exposed to human recombinant leptin could be performed. The surprising 
results reveal that exogenous leptin significantly influences PTH secretion, specifically higher doses of 
leptin result in higher PTH levels secreted into circulation. The long isoform leptin receptor contains 
intracellular motifs capable of interacting with the janus kinase signal transducers and activators of 
transcription (JAK-STAT3) and phosphoinosityl-3 kinase (PI3K) pathways (41, 42). The use of AG490 
as a small molecule inhibitor of the JAK2/STAT3 pathway resulted in suppression of PTH secretion 
further implicating leptin hormone influence over PTH secretion. However, PI3K inhibition by 
LY294002 did not reveal a significant suppression of PTH secretion suggesting that the JAK/STAT 
pathway may be the prominent signaling component for leptin in the parathyroid gland. This data 
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provides an altogether different mechanism to explain the association of elevated leptin hormone and 
PTH levels in the context of parathyroid disease. In this case, the hormonal influence of chronically 
elevated leptin may precede elevated levels of PTH by acting mitogenically on parathyroid cell growth 
and activity, perhaps being a key factor in the development of autonomous hypersecreting parathyroid 
neoplasms. Separate studies have shown that overexpression of cyclin D1 in parathyroid glands results in 
adenoma formation (116), and that leptin primarily induces cyclin D1 expression, as seen in B-cell tumors 
(117). 
The study findings create an interesting foundation for the clinical associations previously 
established. There is now a plausible mechanism in which chronically elevated leptin levels in patients 
who are women and obese predisposes them to the development of higher incidence of parathyroid 
disease by acting mitogenically as suggested by our explant data. There is no previous research data 
elucidating the relationship between leptin, parathyroid hormone (PTH), and the parathyroid gland; it 
remains unclear as to whether high leptin levels come before hyperparathyroid disease, possibly acting on 
parathyroid leptin receptors, or whether hyperactive neoplastic parathyroid glands elevate both PTH and 
leptin simultaneously (see Discussion Figure 1). Perhaps a positive feedback endocrine loop exists 
between leptin and PTH; excess leptin produced by adipose tissue may signal increased PTH secretion by 
parathyroid glands, which acts on PTH receptors of adipose tissue (118-120) to complete the cycle.  
 Many questions remain but it is important to continue exploring these hypotheses, which may 
lead to a greater understanding of the pathogenesis of pHPTH in the context of obesity and leptin; it may 
further explain the connection of pHPTH to related hypertension, bone mineral density changes, and 
vascular calcification disease processes (67, 70-72). Additionally, clarifying our findings and hypotheses 
may further serve as the basis for the development of pharmacological approaches to the treatment of 
pHPTH. 
 In our investigation into leptin and the parathyroid glands, we were determined to understand 
why high leptin levels were clinically associated with high PTH levels in the context of 
hyperparathyroidism. Based on biochemical evidence we have for the presence of leptin mRNA and 
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protein in the parathyroid gland itself, we hypothesized that perhaps parathyroid gland synthesis and 
hypersecretion of leptin along with and similar to PTH could be responsible for high levels of both 
hormones in patients with hyperparathyroidism. During minimally invasive parathyroidectomies, the half-
life of PTH (4, 6, 121, 122) affords intraoperative PTH measurements that allow for real time evaluation 
of whether the diseased parathyroid gland culprit —the sole source of excess PTH secretion—had been 
successfully resected. Under an identical rationale given that the half-life of leptin hormone is about 20 
minutes (86), if the parathyroid gland was a significant source of leptin production we would see a drop in 
the hormone’s circulating serum levels subsequent to parathyroid removal. From our data, the 
hyperparathyroid patients had a drop in their PTH, hyperplasia more than adenomas, by greater than fifty 
percent of their starting serum levels as expected when comparing long term measurements (time point 1 
and 4) and the acute perioperative period (time point 2 to 3). During the same acute perioperative period 
we found that this correlated significantly with a drop in leptin hormone levels in the same patients (from 
time point 2 to 3); this drop in serum leptin levels was again greater for patients with hyperplastic 
parathyroids than those with adenomas. This finding is remarkable in that it further deepens the 
association between high leptin and high PTH levels substantiating that they both decrease acutely after 
parathyroidectomy. Hyperplastic parathyroid patients tend to have much higher PTH levels and leptin 
levels owing to greater parathyroid activity and poor renal clearance, respectively. Although 
postoperatively its expected that PTH levels would dramatically decrease as you take away the source of 
the hormone, continued poor renal clearance and minimal intraoperative fluids would argue against any 
decrease or dilution of leptin serum levels; this is unless the four overactive parathyroid glands removed 
are in fact the actual source of leptin hormone production resulting in an observable decrease in serum 
levels.  
Our control patients, who were absent of hyperparathyroid disease but underwent identical 
operating conditions including surgeon, anesthesia, and incision, had the opposite change in their leptin 
hormone levels subsequent to surgery—they significantly increased compared to patients whom had their 
parathyroid removed. Leptin, as a member of the class 1 cytokine receptor family, has been likened to an 
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inflammatory state marker and would be expected to increase given the acute stresses of surgery and 
conditions of chronic renal insufficiency (123, 124). Furthermore, the diurnal rhythm and secretion 
pattern of leptin reveals that at the time of surgery and under the preoperative fasting conditions, the 
leptin levels of these surgical patients should increase over the perioperative time period. Under normal 
physiologic patterns, these patients are starting surgery at a point where their expected leptin level is at its 
nadir and should subsequently rise toward their peaks—not decrease as seen subsequent to removal of the 
parathyroid glands. Furthermore, the preoperative fasting conditions in all patients, experimental and 
control, should shift this pattern forward such that the patients would be expected to have increased leptin 
levels that occur earlier and reach higher levels (95). The preoperative fasting conditions also explains the 
observed drop in leptin from time point 1 to 2, as fasting results in decreases in leptin levels. 
Although we see a decrease in perioperative leptin levels, there is not a sustained drop as seen 
with the PTH levels at time point 4, two months out from surgery. PTH is a hormone unique to the 
parathyroid gland and resection of a hypersecreting adenoma or four-gland hyperplasia ultimately 
removes the unique source of excess PTH. While we believe that leptin is being produced from the 
parathyroid gland in quantities that significantly contribute to circulating serum levels and is responsible 
for the acute drop in leptin levels after surgical resection, we know that it is not the only source of 
circulating serum levels. Adipose tissue, the primary source of leptin secretion in the body (18), have 
PTH receptors and are known to respond to PTH and drive lipolysis (118-120). Other endocrine 
hormones (neuropeptide Y, growth hormone, and prolactin) have been implicated in the influence of 
lipolysis and leptin secretion by adipose cells (125-127) (see Discussion Figure 2); a sudden drop in PTH 
in this case may result in decreased lipolysis and increased leptin secretion which counteracts the 
observed acute drop in leptin hormones as part of a negative feedback loop over time (similar to NPY). 
Along the same lines, the opposite relationship may exist in which PTH drives lipolysis and leptin 
secretion (similar to GH), and as a result of surgery and the decrease in PTH levels, there is an acute drop 
in lipolysis and leptin secretion that is eventually compensated for by adipose tissue in the long run. We 
are in the process of evaluating fat tissue response to PTH and its influence on leptin secretion. However, 
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further investigation is needed. It will be important to characterize leptin changes more closely, especially 
beyond the two months after surgery.  
Our patient population is representative of previous hyperparathyroid and obese patients from 
previous studies (84, 85). From multivariate analysis, we confirmed that baseline PTH levels were 
dependent on key variables such as parathyroid disease diagnosis, low vitamin D, high creatinine (a 
marker of renal function), and pathologic weight and number of diseased parathyroid glands. Each of 
these variables are stigmatic for parathyroid disease, for example over 80% of patients with 
hyperparathyroidism have resultantly low vitamin D levels (128). Calcium, a key variable found on 
bivariate analysis, was not found to be a significant variable in multivariate analysis. Calcium serum 
levels however tend to be inconsistent and do not correlate with parathyroid disease symptoms as they can 
vary in patients from blood draw to blood draw and from high to normal levels. Interestingly, leptin has 
been implicated in suppressing vitamin D production in the renal system and may partly explain why low 
vitamin D levels are a much more consistent variable despite calcium levels fluctuating (82-85, 114). For 
baseline leptin levels, the diagnosis of hyperparathyroidism, increased BMI, and female gender were key 
variables in a multivariate model; this further substantiates the clinical association between high leptin 
levels, a marker of obesity, high PTH levels, a marker of hyperparathyroid disease, and the finding that 
the two diseases combined increase serum leptin to levels greater than in either disease condition alone 
(85). Interestingly, there was a correlation between BMI and the weight of parathyroid glands removed. 
This supports a mechanistic argument for high BMI and resultant serum leptin levels acting as a trophic 
factor to promote parathyroid adenoma disease development. Furthermore, females have higher leptin 
levels than men, and coincidently have a higher prevalence of hyperparathyroid disease. 
Postoperative changes in serum PTH levels are associated with starting baseline PTH levels as 
well as the number of parathyroid glands removed. Patients with multi-gland disease are typically 
affected by secondary hyperplasia and undergo three and a half gland resections. As these patients 
typically start at serum levels of PTH significantly higher than their adenoma counterparts, they are 
observed to have more significant changes in serum PTH along with more glands resected. Postoperative 
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changes in serum leptin levels were significantly related to surgical removal of the parathyroid glands in 
comparison to control surgical removal of the hemi-thyroid. Leptin levels changed by as much as 
5.7ng/mL in the diseased population, which is equivalent in quantity to normal physiologic serum levels 
(1.2-9.5ng/mL in males, 4.1-25.0ng/mL in females). This again substantiates the direct link between 
serum leptin levels and diseased parathyroid glands. We have biochemical evidence showing that leptin 
mRNA and protein are absent from thyroid tissue, as taken out in our control patients. Furthermore, 
additional studies have only alluded to peripheral interactions of leptin and thyroid hormones, but not 
production by the thyroid gland itself (19). Also, leptin level changes are associated with starting leptin 
levels, age, and BMI. The connection between obesity and hyperparathyroidism is strong. Although bone 
mineral density was not a significant factor associated with baseline or changes in leptin levels, the 
association of changes with age alludes to differences in leptin levels in the postemenopausal state and the 
higher prevalence of hyperparathyroid disease in the elderly population (67, 68). Leptin is thought to 
increase bone mass density (69) by several mechanisms, but in the context of primary 
hyperparathyroidism osteoporosis is inevitable without treatment.  
Leptin levels significantly decrease after the removal of diseased parathyroid glands in 
comparison to control subjects. While the decreased substantiates a link between the hormone and the 
parathyroid gland, further investigations will be important in elucidating the physiologic and clinical 
significance of this relationship. The clinical characteristics of our patient population—elderly, pre-
hypertensive, and overweight—allude to the comorbidities of parathyroid disease. Hyperparathyroid 
patients typically have blood pressure, glucose intolerance and weight control problems. Diabetic patients 
with primary hyperparathyroidism showed improvement in glucose control after parathyroidectomy 
(129). Furthermore, Hagstrom et al. (130) demonstrated that dyslipidemia in the same patients was 
normalized after parathyroidectomy. There is an overwhelming literature linking leptin to glucose and 
weight control, and more recently to the pathogenesis of cardiovascular disease—including hypertension 
and atherosclerosis (70, 71). By investigating leptin in the parathyroid glands, perhaps we can elucidate 
the link between parathyroid disease and the increased prevalence of these comorbidities.  
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One place to start may be to look at SNP and VNTR polymorphisms in the leptin and leptin 
receptor gene as a meta-analysis study looking at leptin gene and leptin receptor gene polymorphisms 
found that allelic frequencies (78) showed ethnic variation. Furthermore, polymorphisms in the leptin 
receptor gene have been related to multiple disease predispositions (78, 131-134). Although mutations in 
the human ob gene are very rare, evaluations of intronic/exonic variations and mutations in the leptin 
receptor and resultant impaired signaling (135-138) may provide further insight into disease mechanisms.  
  
	  	   91	  
Figures of Discussion (1-2) 
 
 
 
Figure 1: Multiple Hypotheses 
 
 
 
Our study for 1) shows that Leptin is a new functional and physiologically relevant parathyroid gland 
hormone that is released into systemic circulation. Secondly, 2) explant experiments suggest that 
exogenous leptin exposure influences PTH secretion, specifically higher doses of leptin result in higher 
PTH levels secreted from the parathyroid, and blocking such pathway results in diminished levels of PTH. 
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Figure 2: Counter-Regulatory Hormones Influencing Adipocytes 
 
 
 
 
A multitude of counter-regulatory hormones such as growth hormone, prolactin, and NP-Y have been 
shown to influence adipocyte lipolysis and leptin secretion; perhaps PTH has an influence over leptin 
secretion by adipocytes as well.  
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Summary of Future Directions
 
Experiment 
 
Retrospective Study of Leptin and Leptin 
Receptor Polymorphism in Cohort of 
Hyperparathyroid Patients 
 
JAK/STAT Pathway Phosphorylation 
Antibody Array Assay  
 
Ob/Ob Mice Parathyroid Xenograft and 
Evaluation of Leptin Effects on Biophysical 
Function 
 
PTH Exposure to Fat Explants and Evaluation 
of Changes in Lipolysis and Leptin Secretion 
 
Epinephrine Exposure to Parathyroid Explants 
and Evaluation of Leptin Secretion 
 
Develop Transgenic Mice Model of 
Hyperparathyroidism 
 
Stem cell Differentiation into Parathyroid 
Secretory Cell  
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In progress 
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